(Circulation. 1996;94:1996-2012.)
© 1996 American Heart Association, Inc.
Articles |
Multiple Mechanisms in the Long-QT Syndrome
Current Knowledge, Gaps, and Future Directions
the Sudden Arrhythmic Death Syndromes (SADS) Foundation (*see "Appendix" for participants).
Correspondence to Dan M. Roden, MD, Director, Division of Clinical Pharmacology, 532 Medical Research Bldg I, Vanderbilt University School of Medicine, Nashville, TN 37232-6602.
 |
Abstract |
|---|
 Top Abstract IntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
Abstract The congenital long-QT syndrome (LQTS) is characterized by prolonged QT intervals, QT interval lability, and polymorphic ventricular tachycardia. The manifestations of the disease vary, with a high incidence of sudden death in some affected families but not in others. Mutations causing LQTS have been identified in three genes, each encoding a cardiac ion channel. In families linked to chromosome 3, mutations in SCN5A, the gene encoding the human cardiac sodium channel, cause the disease. Mutations in the human ether-a-go-go–related gene (HERG), which encodes a delayed-rectifier potassium channel, cause the disease in families linked to chromosome 7. Among affected individuals in families linked to chromosome 11, mutations have been identified in KVLQT1, a newly cloned gene that appears to encode a potassium channel. The SCN5A mutations result in defective sodium channel inactivation, whereas HERG mutations result in decreased outward potassium current. Either mutation would decrease net outward current during repolarization and would thereby account for prolonged QT intervals on the surface ECG. Preliminary data suggest that the clinical presentation in LQTS may be determined in part by the gene affected and possibly even by the specific mutation. The identification of disease genes in LQTS not only represents a major milestone in understanding the mechanisms underlying this disease but also presents new opportunities for combined research at the molecular, cellular, and clinical levels to understand issues such as adrenergic regulation of cardiac electrophysiology and mechanisms of susceptibility to arrhythmias in LQTS and other settings.
Key Words: genes • arrhythmia • long-QT syndrome
|
Introduction |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
The idiopathic or congenital LQTS1 is an inherited disease characterized by prolonged ventricular repolarization and a high risk for sudden cardiac death. Most of the life-threatening arrhythmias in LQTS occur during physical or emotional stress, although in some families, sudden death occurs during sleep. Thus, LQTS has been regarded as an important example of neurally mediated sudden cardiac death unrelated to coronary artery disease. Studies of the mechanisms underlying arrhythmias in LQTS have integrated clinical science, basic electrophysiology, and molecular genetics. Understanding of these mechanisms not only would contribute to improved therapy for patients with this intriguing, albeit uncommon, disease but also would provide information important for understanding neurally mediated arrhythmogenesis in other situations.
To define the state of the art in understanding LQTS, a multidisciplinary task force was convened in early 1995 by the Sudden Arrhythmia Death Syndromes Foundation. Since that time, important advances have occurred in studies of the molecular genetics and electrophysiology of LQTS. In this review, background information on the clinical and ECG features of LQTS and the probable underlying electrophysiological mechanisms will first be described. The molecular defects that have been linked to LQTS will then be presented, followed by a discussion of how these findings provide the groundwork for new lines of inquiry at the molecular, cellular, and clinical levels.
|
Background |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
Clinical Features of LQTS
The inherited LQTS is characterized by recurrent syncope (often during exercise or emotional stress), QT prolongation and T- and U-wave abnormalities on the ECG, and sudden death. One form of LQTS, described in 1957 by Jervell and Lange-Nielsen,2 includes deafness and probable autosomal recessive inheritance.2 3 4 A similar condition, without deafness and with autosomal dominant transmission, was subsequently reported independently by Romano et al5 and Ward.6 Relatively few cases of the Jervell–Lange-Nielsen form are currently recognized, whereas the Romano-Ward variant is recognized with increasing frequency. Most of the information currently available regarding the syndrome relates to the autosomal dominant (Romano-Ward) form. There is considerable variability in the clinical presentation, and diagnosis is sometimes difficult. When the correct diagnosis is not made, syncopal events often are attributed incorrectly to a primary seizure disorder or to vasovagal events. To assist in diagnosis, criteria incorporating ECG, clinical, and family history findings have been developed (Table 1
).7 8
|
Syncope and Sudden Death
The cause of syncope in LQTS is the polymorphic ventricular tachycardia torsades de pointes. The term "torsades de pointes" (twisting of the points) was coined in 1966 by Dessertenne,9 who used it to describe the pause-dependent polymorphic ventricular tachycardias he observed in an elderly patient with syncope, heart block, and marked QT prolongation. Although others have used this term virtually interchangeably with all forms of polymorphic ventricular tachycardia, most authorities would confine its use to those polymorphic ventricular tachycardias with a distinctive time-dependent change in electrical axis ("twisting of the points"), along with at least some of the QTU abnormalities described here.
The onset of torsades de pointes in patients with LQTS can follow one of two patterns. In some patients, bradycardia with associated marked QT prolongation (which appears to be greater than what would be expected merely from rate slowing) is responsible. In other patients, adrenergic stress with sinus tachycardia is the rule. Nevertheless, even in the latter group, torsades de pointes often develops in a pause-dependent fashion, ie, immediately after a sinus beat after a postectopic pause (Fig 1A). Most episodes of sudden death in LQTS almost certainly result from ventricular fibrillation triggered by torsades de pointes, but the mechanisms whereby this transition occurs are unknown. The frequencies of syncope and sudden death vary from family to family. These events are often precipitated by sudden autonomic stimuli such as anger, fear, or startle, although some sudden deaths occur during sleep or rest. These presentations tend to cluster in families and thus, as described below, may reflect different mutations in different families.
|
Sex
Equal numbers of males and females should be affected in an autosomal dominant condition. This has been shown for LQTS families in which affected individuals were identified by use of genetic markers.10 However, several studies in which the diagnosis was ascertained by ECG or by symptom criteria show a predominance of females.11 12 13 This observation raises the possibility of a contribution by the products of other genes ("modifier genes") to prolongation of the QT interval in women or to its shortening in men. Interestingly, a similar female preponderance also has been described in drug-associated torsades de pointes,14 an observation that supports the link discussed below between the inherited and drug-induced arrhythmias.
QT Prolongation
In most patients with LQTS, the rate-corrected QT interval (QTc by Bazett's formula) is >0.46 seconds, but some affected individuals have QTc values in the normal to upper-normal range of 0.41 to 0.45 seconds.10 QT prolongation is absent in 
5% to 10% of gene carriers, and it has also been reported that syncope or cardiac arrest can occur in 5% of LQTS family members who have an apparently normal QT interval.11 These findings suggest reduced penetrance or contributions by modifier genes or environmental factors (such as electrolyte abnormalities) to the clinical manifestations of LQTS.
T and U Waves
The ECG changes in LQTS include considerably more than simple prolongation of the QT interval. Most of the characteristic ECG findings are consistent with the concept that repolarization in LQTS displays substantial spatial and temporal heterogeneity.15 For example, QT dispersion, as assessed by the difference between the longest and shortest QT intervals on a 12-lead ECG, is increased in LQTS, indicating spatial heterogeneity in repolarization.16 The normal range for QT dispersion determined in this fashion is 46±18 ms, and in patients with LQTS, it is 133±21 ms. In addition, the T wave often has a notched or biphasic appearance.17 These findings, in turn, suggest that abnormal AP prolongation in LQTS may occur to a greater extent in some cells than in others. As described below, it is increasingly recognized that even under normal conditions, APs in the ventricle are highly heterogeneous, which suggests that different ion channel lesions might produce different and distinctive ECG patterns. Indeed, specific T-wave patterns have been associated with specific gene defects (Fig 1B
),18 although overlap among patterns may exist.
Another manifestation of spatially heterogeneous repolarization is a regional left ventricular wall motion abnormality,19 observed in approximately half the patients investigated; it is more prevalent among those with syncope and is abolished by verapamil.20 An unusual but diagnostic ECG manifestation of LQTS is T-wave alternans (Fig 1C), in which the T wave is not only prolonged and morphologically bizarre (implying spatial heterogeneity of repolarization) but also varies on a beat-to-beat basis21 22 and with sympathetic activation,21 23 which indicates temporal variability in repolarization.
In addition to bifid T waves, U waves seem prominent in some patients with LQTS. Whereas U waves can occur in normal subjects with sinus bradycardia, U waves in some patients with LQTS are exaggerated, although objective data addressing this point are not available. Like T waves, U waves can also be labile and display alternans; in fact, marked prolongation of the QT interval in LQTS can represent a very prominent U wave (Fig 1C).
Another important ECG manifestation of LQTS is sinus bradycardia and decreased heart rate with exercise. Again, the extent to which this is manifest in an individual subject is highly variable, which indicates that either certain gene defects are more likely to be associated with this manifestation of the disease than others or expression of modifier genes determines whether an individual subject develops sinus bradycardia.
Provocative Tests
Some ECG abnormalities, such as obvious QT prolongation and deformity with T-wave alternans, are diagnostic of LQTS. Conversely, borderline QT-interval prolongation is much more sensitive but far less specific. To circumvent difficulties in diagnosis, some have advocated the use of provocative tests, such as determination of the extent of QT-interval shortening with treadmill exercise or evaluation of the presence of U waves or arrhythmias with epinephrine or isoproterenol infusion.24 25 However, exercise under controlled conditions seldom provokes torsades de pointes, whereas spontaneous episodes often arise with the combination of exercise and emotional stress. Moreover, it is now apparent that the QT response to exercise may be determined to a large extent by the specific mutation causing LQTS in an individual. Thus, subjects with the sodium channel inactivation defect on chromosome 3 described below not only appear to have a distinctive ECG pattern at rest (Fig 1B)18 but also are reported to display marked shortening of the QT interval during exercise.26 In these subjects, the onset of torsades de pointes is usually bradycardia dependent. Conversely, subjects with defects linked to a potassium channel gene defect on chromosome 7 seem to display a different QT pattern at rest, abnormally long QT intervals during exercise, and adrenergic-dependent onset of torsades de pointes. Further studies are seeking to verify and expand these preliminary observations. These genotype-phenotype correlations not only provide important clues to the mechanisms underlying arrhythmogenesis in LQTS but also may become important for clinicians as specific therapies for individual genetic subtypes of LQTS are identified and tested in prospective trials.
Therapy
The mortality of untreated symptomatic patients with LQTS exceeds 20% in the year after their first syncopal episode and approaches 50% within 10 years.7 With therapy, this can be reduced to 3% to 4% in 5 years. Although no placebo-controlled, randomized, clinical trials have been undertaken, strong evidence supports the use of antiadrenergic interventions as mainstays of therapy. The trigger for many life-threatening events is emotional or physical stress, probably associated with a sudden increase in sympathetic activity. ß-Adrenergic blockade prevents new syncopal episodes in 75% of patients. Among those with persistent syncope despite ß-blockade, left cardiac sympathetic denervation appears to provide significant additional protection.27 28 In patients with evidence of pause- or bradycardia-dependent arrhythmias, cardiac pacing is a rational and effective adjunct to ß-blockers.29 30 The acute therapy of torsades de pointes in LQTS includes cardioversion, elimination of any provoking factor such as hypokalemia or the concomitant use of QT-prolonging antiarrhythmic or other drugs, and ß-blockade.
Rarely, torsades de pointes persists despite therapy with a combination of ß-blockade, left cardiac sympathetic denervation, and pacing. The implantable cardioverter-defibrillator has been used successfully in this setting, although it is not first-line therapy because shocks from the device can precipitate further emotional distress and thus further arrhythmias. Other pharmacological interventions have been used sporadically or have been proposed on the basis of experiments in vitro or in animal models; these include 
-blockers, calcium channel blockers, potassium channel openers, right cardiac sympathetic denervation, or sodium channel blockers.24 25 31 32 33 34 35 None of these therapies have been tested in sufficiently large numbers of patients that they can be viewed as anything but experimental in highly refractory patients.
With the identification of the precise molecular defect in some cases of LQTS, specific mechanism-based therapies may be developed and tested. For example, preliminary reports suggest that the sodium channel blocker mexiletine may be useful in shortening the QT interval in patients with a defect linked to the sodium channel gene on chromosome 3,26 and in vitro studies provide a rationale for this approach.36 37 38 39 This approach, however, remains highly speculative and obviously cannot be taken to include any sodium channel blocker, since some prolong the QT interval. Further studies in defined subsets of patients, with the end points being not QT-interval measurements but rather syncope and sudden death, will be required before specific recommendations for long-term, mechanism-based therapy can be formulated.
|
Mechanisms Underlying LQTS |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
Competing Hypotheses to Explain LQTS
The clinical features of LQTS led to the formulation of two hypotheses to explain its pathogenesis40 : (1) The striking adrenergic dependence of symptoms and the beneficial effect of antiadrenergic interventions led to the suggestion that there was an abnormality (eg, an imbalance) in the sympathetic innervation to the heart. Such a formulation would explain abnormal sinus rate, abnormal repolarization (possibly), and adrenergic dependence of arrhythmias and their correction by antiadrenergic drugs. (2) Many of the ECG manifestations of LQTS are indistinguishable from those in patients with "acquired" QT-interval prolongation and torsades de pointes, most often seen during therapy with drugs whose major effect is to alter cardiac ion currents. Thus, a second theory was that LQTS was due to an "intrinsic" abnormality in the mechanisms responsible for cardiac repolarization. Such an intrinsic abnormality would explain the long QT interval and could, as described below, also explain the arrhythmias and even their adrenergic dependence. At all three chromosomal loci at which mutations causing LQTS have been identified (accounting for >90% of cases), the mutated gene encodes a cardiac ion channel protein. Ion channels are structures that are responsible for currents that determine cardiac repolarization; thus, LQTS is due to an intrinsic abnormality in the vast majority of patients.
Ion Channels and Currents
Ion channels are individual proteins or complexes of proteins that reside in the cell membrane. The distinguishing characteristic of ion channel proteins is that, in response to such exogenous signals as a change in voltage across the cell membrane, they can form pores for the entry or egress of specific ions (sodium, potassium, calcium, etc). Thus, individual currents created by this movement of charged ions reflect the function of specific ion channel proteins. The application of whole-cell and patch-clamp techniques to cardiac cells has allowed electrophysiologists to identify multiple currents that flow across the cell membrane to determine cardiac repolarization. A key feature of the cardiac cell membrane during repolarization is that even very small changes in individual ion currents can markedly alter the delicate balance between inward and outward current flow during repolarization and thereby prolong or shorten the AP. This fundamental concept provides the basis for understanding how subtle abnormalities in individual ion channel genes can cause LQTS.
Many of the genes that encode ion channel proteins have been identified (Fig 2, Table 2). The features of a given ion current often can be replicated by expressing a single "-subunit" gene in systems such as the Xenopus oocyte. However, for many ion channels, the presence of one or more ancillary proteins (often called ß-subunits), the products of different genes, may be required for the faithful recapitulation of all the current's physiological features. Description of the relationship between individual ion currents identified by electrophysiological studies and individual ion channel gene products, whose function is commonly characterized in heterologous expression systems such as the Xenopus oocyte, is an area of active investigation.
|
|
Cellular Mechanisms of Arrhythmogenesis in LQTS
Early Afterdepolarizations
Since the QT interval is a surface manifestation of APD, any theory to explain arrhythmias in LQTS should include AP prolongation. Major advances in the understanding of the relationship between abnormally long QT intervals and arrhythmogenesis came in the early 1980s, when in vitro and in vivo studies linked AP prolongation to the development of early afterdepolarizations (EADs) in conducting system tissue (Purkinje fibers).41 42 43 EADs are oscillations or deformities in the repolarization phases (plateau [early] and phase 3 [late]) of the AP (Fig 3). Some studies suggest that the mechanisms and possible clinical consequences of early and late EADs may differ. When EADs are observed in vitro, they often give rise to triggered APs. Such triggered activity would produce premature beat(s) if propagated in the whole heart. EADs are induced by interventions that decrease repolarizing (potassium) currents (eg, administration of cesium or antiarrhythmic drugs41 43 44 ) and/or that increase inward currents carried by calcium or sodium.45 46 47 These changes may produce EADs directly, or they may alter the trajectory of the AP to produce secondary changes in otherwise normal ion currents that then result in EADs (Fig 3). The candidate currents may be inferred from Fig 2; experimental and modeling studies suggest that increased inward current through L-type calcium channels or through sodium-calcium exchange is responsible.48 49 50 The triggered upstroke is most likely due to inward current through L-type calcium channels at positive potentials, whereas upstrokes occurring later during phase 3 (eg, see Fig 3) might be due to inward current through sodium or T-type calcium channels. Triggered activity arising from EADs may initiate or help maintain torsades de pointes, as described below.
|
T-Wave Alternans
Multiple abnormalities in ion current flow across cell membranes could also explain T-wave alternans. The general principle, illustrated in Fig 4, is that QT alternans reflects a failure of all ion channels to recover back to their rested state during diastole before the next AP. Alternans thus may be exaggerated when diastole is shortened (by fast rates or AP prolongation).51 The development of T-wave alternans in LQTS could thus reflect AP prolongation itself (with shorter diastolic times); abnormally slow deactivation of a potassium current (eg, see Fig 4) or abnormal intracellular calcium handling may also play a role.51 52 53 54 55 The finding of alternans phenomena at both fast and slow rates in LQTS (Fig 1C) suggests that multiple mechanisms may be involved. The morphology of the QT interval on the surface ECG is determined in part by the heterogeneity of the underlying APDs; thus, the presence of repolarization alternans provides further evidence for the temporal and spatial heterogeneity of repolarization in LQTS.
|
M Cells
A problem in attributing the LQTS phenotype to EADs and EAD-related triggered activity in Purkinje fibers is that the specialized conducting system represents only a very small portion of the mass of the ventricle and that EADs are much more difficult to elicit in ventricular cells than in Purkinje fibers. Therefore, phenomena such as bifid T waves or U waves that presumably represent delayed repolarization of substantial portions of the ventricle are difficult to explain. An answer to this apparent paradox may lie with the identification in the midmyocardium of a large population of cells, called M cells, with distinctive conducting system–like electrophysiological properties.56 M cells display marked AP prolongation in response to stimuli such as hypokalemia, slow driving rates, or the presence of AP-prolonging drugs.57 In addition, EAD-related triggered activity is common in M cells with these stimuli. Some computer simulations have even suggested that apparent EADs recorded by use of monophasic AP methods may actually reflect marked prolongation of APs in M cells with normal APs in endocardium, in the absence of EADs in either tissue.58
In Vivo Mechanisms Underlying Torsades de Pointes
The mechanisms that underlie sustained episodes of torsades de pointes are not well understood. One possibility is raised by the observation that driving the heart rapidly at different rates from multiple foci produces a polymorphic ECG pattern.59 60 EAD-related triggered activity arising in multiple loci at different rates could similarly result in the distinctive ECG appearance. Triggered activity arising from EADs has also been reported in experimental animals, and it seems to produce many of the ECG features of torsades de pointes.42 46 61 A second possibility is that torsades de pointes result from reentrant excitation. In this scenario, the unidirectional block required for reentry is created by the M-cell layer with its abnormally prolonged APs. The reentrant pathway would vary in a relatively organized fashion from beat to beat as the site of reentry shifted along the functional barrier created by the M-cell region.62 63 A number of studies have identified heterogeneity of repolarization as an important risk factor for torsades de pointes in both LQTS and the drug-acquired forms.16 64 65 This lends support to the concept that reentrant excitation may be important in the maintenance of an episode of the arrhythmia. Finally, it is possible that torsades de pointes occurs as a result of EADs in the conducting system and the fact that propagation to the ventricle varies on a beat-to-beat basis, perhaps as a consequence of variable conduction block in the M-cell layer. Studies suggesting that the arrhythmia originates in the subendocardium support such a hypothesis.66
|
Chromosomal Defects in LQTS |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
The first chromosomal locus to which LQTS was linked was in the telomeric region of chromosome 11 (11p15.5) (LQT1; see Fig 5
). The initial analysis reported by Keating67 was performed in a very large family and demonstrated tight linkage, with a logarithm of the odds score >15, to the H-ras-1 locus in this region. In other words, there was a <1 in 1015 likelihood that the abnormality was not at this locus. This was an intriguing finding, because the H-ras locus encodes an oncogene that may play a role in modulation of cardiac potassium current by intracellular signaling pathways68 ; thus, a linkage to the adrenergic features of LQTS was suggested. However, subsequent studies excluded H-ras-1 as the disease gene, because no mutations were found on sequence analysis,69 70 recombination events between the disease phenotype and H-ras-1 were identified,69 70 and fine mapping of this region suggested that the disease gene was more centromeric.71 In early 1996, mutations in a newly cloned gene, KVLQT1, were identified as the cause of LQT1.72 No information is yet available on the function of KVLQT1, although its inferred partial amino acid sequence strongly suggests that it encodes a potassium channel. mRNA transcripts hybridizing to a KVLQT1 probe are present in the human heart, kidney, placenta, and lung, with greatest abundance in the heart.
|
Available evidence indicates that >50% of affected families link to KVLQT1,72 and all of the first seven families studied were linked to the chromosome 11p15.5 locus.73 However, Towbin and colleagues74 reported evidence of genetic heterogeneity in LQTS shortly after the initial reports, and subsequent studies identified families that failed to link to this locus, indicating that abnormalities in other chromosomal locations could cause LQTS.75 76 77 78 79 In late 1994, Jiang and colleagues80 provided evidence for linkage to chromosome 7q35-36 (LQT2) in nine families and linkage to chromosome 3p21-24 (LQT3) in three other families. A fourth locus has been identified at 4q25-27 (LQT4) in a single large French kindred81 ; this family is unusual because there is a high incidence of atrial fibrillation along with the LQT phenotype. In addition, several families are excluded from linkage at all four known regions, suggesting at least one more and possibly several more disease-causing genes for LQTS. The gene encoding the Jervell–Lange-Nielsen form associated with congenital deafness has not been identified. LQT1 and LQT2 seem to be the most common forms of the disease and LQT4 the rarest, with only the single kindred reported to date.
Once a chromosomal locus linked to a disease such as LQTS is identified, two general approaches can be used to identify the disease-causing gene. One is the "positional candidate gene" approach. In this method, once a chromosomal locus is identified, it is compared with that of genes whose dysfunction might reasonably be expected to result in the abnormal phenotype. In the case of LQTS, this would include genes that encode cardiac ion channels (Table 2) as well as genes involved in regulation of sympathetic activity in the heart. This candidate gene approach was used successfully to identify mutations in two genes, HERG on chromosome 782 and SCN5A on chromosome 3,83 the causes of LQT2 and LQT3, respectively. In the second overall approach, a candidate gene is identified not on the basis of physiological considerations but rather through cloning of large portions of the genome in the region linked to the disease. Exons identified within these cloned regions are then analyzed to determine whether mutations segregating with the disease phenotype are present. This positional cloning and mutational analysis approach was used to identify mutations in KVLQT1 on chromosome 11,72 the cause of LQT1. As shown in Table 3, mutations have been identified in multiple loci in different kindreds for each of the three LQTS disease genes.
|
Defects in Outward Current and LQTS
The first potassium channel genes to be cloned were isolated from the Shaker mutant (so called because it shakes when exposed to ether) of the fruit fly Drosophila melanogaster.84 Genes of the Shaker family (called Kv1.x) have also been isolated in humans, and some (eg, Kv1.5) are expressed in the heart.85 Subsequently, Shaker-like genes were cloned from a different Drosophila mutant, ether-a-go-go (eag).86 Eag does not seem to be present in humans, but in 1994, Warmke and Ganetzky87 reported the cloning of a human eag-related gene (HERG) from a human hippocampal cDNA library. At the time HERG was cloned, its function was not established, although its inferred amino acid sequence did exhibit the six membrane-spanning segments motif seen in other potassium channels such as Shaker. HERG mRNA transcripts have been found in heart, and mutations in multiple regions of the HERG gene have been identified as the cause of LQT2.82 The coding sequence is unusually rich in cytosine-guanosine pairs, which may predispose this gene to mutagenesis. When HERG is expressed in Xenopus oocytes,88 89 most of the major physiological features of the rapidly activating cardiac delayed rectifier potassium current (IKr) are observed: inward rectification, relatively rapid activation, and block by drugs of the methanesulfonanilide class.90 91 In addition, IKr, unlike most other potassium currents, increases when extracellular potassium is increased.88 92 Lowered extracellular potassium has also been found to markedly potentiate drug block of IKr93 ; this finding may explain the relationship between hypokalemia and the development of torsades de pointes, and it is consistent with preliminary reports suggesting that elevation of extracellular potassium may increase IKr and shorten QT in some patients with LQTS on a congenital or drug-induced basis.93A Interestingly, despite the adrenergic features of LQTS and despite a cyclic nucleotide–binding domain on HERG (which is actually the site of one mutation), IKr is generally thought to be unaffected by ß-adrenergic stimulation.94 95 It is likely that KVLQT1 also encodes a potassium channel, on the basis of its inferred amino acid sequence, which contains both the six membrane-spanning segments motif and an ion-conducting pore sequence common to potassium channel proteins.72
Other potassium channel proteins (eg, those of the Shaker family) are thought to coassemble in groups of four (tetramers),96 97 with or without ancillary ß-subunits,98 99 100 to form functional channels. Since HERG proteins exhibit a topology similar to that of Shaker proteins, coassembly of a single abnormal HERG subunit with even three normal ones might be sufficient to disrupt IKr. This "dominant negative" effect would explain the autosomal dominant nature of LQT2. Two intragenic deletions of HERG have been identified (Table 3; Fig 6A). One results in a stop codon within the region encoding the S1 transmembrane domain; another results in a nine-amino-acid deletion within the S3 transmembrane domain. These mutant proteins do not form functional channels and do not interact with normal HERG channels when coexpressed in Xenopus oocytes.101 Thus, individuals with these mutations would be predicted to express half the normal number of channels carrying IKr. Three missense mutations that result in single amino acid substitutions in the S5 transmembrane region (A561V), pore region (G628S), and S2 transmembrane region (N470D) have also been evaluated.101 A561V and G628S mutant channels do not express detectable currents in Xenopus oocytes but do cause a dominant negative suppression of wild-type HERG function in oocytes injected with RNA encoding both wild-type and mutant channels (Fig 6B). N470D mutant proteins form functional channels with altered kinetic properties, and coexpression of normal and N470D channels reveals a dominant negative effect. The order of severity in reduction of HERG function for mutations characterized to date is G628S (most severe) > A561V > N470D > intragenic deletions (least severe).101 It will be interesting to determine whether this spectrum of HERG channel dysfunction correlates with the severity of disease in patients with LQT2.
|
Pause-dependent torsades de pointes is a well-recognized complication102 of therapy with drugs that specifically block IKr (eg, dofetilide,103 almokalant104 ) or drugs that block IKr and also exert other electrophysiological effects (eg, quinidine,93 105 sotalol,90 106 ibutilide107 108 ). Thus, the identification of mutations in HERG as a cause of LQTS provides an important link between LQTS and drug-associated torsades de pointes. The [K+]o sensitivity of IKr may help explain why hypokalemia is such an important risk factor for torsades de pointes; in addition, drug-induced IKr block is relieved by raising [K+]o,93 and recent studies suggest marked QT shortening in LQT2.93A These data raise the possibility that drugs that interact with a potassium-binding site on HERG might be beneficial in LQT2. The bradycardia characteristic of both LQTS and the drug-induced form suggests that IKr can play an important role in sinus node function. Interestingly, although the onset of torsades de pointes is usually pause dependent in drug-related cases, a role for adrenergic stimulation has also been suggested by the observation that heart rate seems to increase just before the onset of the arrhythmia.109
Many other outward currents have been identified by electrophysiological studies in cardiac cells, and clones corresponding to some of these have been identified (Fig 2). It is also increasingly clear that ß-subunits may be important modulators of the function or level of expression of some of these channels. Defects in any of these channels or ß-subunits could conceivably cause LQTS. Genes encoding K+ channels that lack the six membrane-spanning segment motif of Shaker and HERG have also been cloned. The inward rectifiers (IRK family) have a topology similar to that of Shaker and HERG, although they appear to represent truncated versions of these channels, with only two putative membrane-spanning segments.110 111 112 113 The minK gene encodes a short protein (130 amino acids).114 115 116 When minK is expressed in Xenopus oocytes, a current strongly resembling the slowly activating delayed rectifier (IKs) is recorded. However, there is considerable controversy as to whether minK encodes this current directly or acts as a regulator or activator of other genes that are responsible for IKs or other ion currents, including IKr.117 118 Other outward channels that control the fine balance between inward and outward current during repolarization include the transient outward current (Ito), a high-conductance plateau channel (IKp),119 and chloride channels.120 121 An important example of the latter is the cAMP-activated chloride current (ICl-cAMP) that appears to be encoded by the cystic fibrosis transmembrane conductance regulator, the gene whose dysfunction causes cystic fibrosis.122 Potassium channels that may play especially important roles in repolarization during pathological stress such as stretch123 or myocardial ischemia124 have also been identified; well-characterized examples include potassium channels regulated by ATP, acetylcholine, and intracellular sodium.125 126 The maintenance of normal intracellular ionic homeostasis requires normalization of intracellular calcium and sodium after each AP. Extrusion of sodium and calcium by ionic pumps is electrogenic (ie, results in a net transmembrane current that can be inward or outward depending on specific physiological conditions), and so dysfunction of these pumps could also underlie LQTS.
Defects in Inward Current and LQTS
Mutations in SCN5A, the gene encoding the cardiac sodium channel -subunit, are the cause of LQT3.83 127 Three LQTS mutations in this large protein have been identified (Table 3; Fig 7A). Two are point mutations, and the third is a nine-nucleotide deletion that results in deletion of three amino acids—lysine (K), proline (P), and glutamine (Q)—in the intracytoplasmic loop linking domains III and IV of the channel protein. It has been known for several years that mutations in the III-IV linker can disrupt sodium channel inactivation.128 129 Moreover, toxins that inhibit sodium channel inactivation can cause EADs and triggered activity in vitro and long-QT–like arrhythmias in vivo.45 46 130 The 
KPQ mutation results in a much more subtle change in the behavior of the sodium channel. Macroscopic activation and inactivation seem near normal. However, the wild-type channel generally inactivates completely during long depolarizing pulses, whereas the KPQ mutant exhibits a small, sustained inward current, even with long depolarizing pulses (Fig 7B).36 This small inward current is most likely sufficient to disrupt the normal balance between inward and outward currents during the plateau phase and hence prolong cardiac APs. At the single-channel level, the maintained inward current reflects a sporadic failure of the sodium channel to inactivate normally. Rather, in 3.5% of sweeps, it displays continuous opening and closing behavior and occasionally even remains open at the end of a very long depolarizing pulse. Presumably, this abnormal inactivating behavior reflects a failure of the III-IV linker to appropriately effect inactivation. The abnormal "late" inward current would be produced by even a single abnormal allele, and thus this "gain of function" explains the autosomal dominant nature of LQT3. The functional consequences of the two described point mutations (Table 3; Fig 7A) seem to be qualitatively similar but perhaps less severe than those for the KPQ mutant.38 Thus, as in the case of the HERG mutations in LQT2, there may be a spectrum of severity of sodium channel dysfunction in LQT3 and thus a possible spectrum of disease severity among individuals with LQT3.
|
Whether the maintained inward sodium current completely accounts for the LQT3 phenotype is unknown. It is possible, for example, that increased intracellular sodium loading consequent to maintained inward sodium current could in turn activate electrogenic sodium-calcium exchange, thereby blunting the extent of AP prolongation while increasing intracellular calcium. Increased intracellular calcium, in turn, might account for sensitivity to adrenergic stimuli or might be directly arrhythmogenic.131 This scenario would be most prominent at rapid rates (when sodium loading is greatest) and thus is consistent with the report that LQT3 patients appear to display relatively normal (or even supernormal) QT shortening during exercise or other tachycardia-related sodium loading.26
Since the cardiac sodium channel is not thought to play a major role in sinus node function, it is not clear how the SCN5A defect explains the sinus bradycardia seen in LQTS, and specifically in LQT3.26 Perhaps sodium channels are more important in determining heart rate than previously appreciated; alternatively, variable contributions of modulator genes may be responsible. The KPQ mutation also lies close to a putative protein kinase C phosphorylation site, so it is conceivable that the response of the mutant channel to adrenergic stimulation will prove to be abnormal.
Defects in other structural proteins encoding inwardly conducting ion channels could similarly alter inward current and thus cause other forms of LQTS. The L-type calcium channel has been cloned (Table 2), but a T-type clone has not been identified. In addition, the syndrome could be attributable to defects in accessory subunits that can modify levels of expression and/or kinetics of these principal -subunits. An accessory sodium channel ß-subunit has been isolated; coexpression of this subunit with brain sodium channel -subunit in Xenopus oocytes increases sodium current and accelerates its activation and inactivation.132 However, whether the ß-subunit, which is detectable in heart, is necessary to faithfully recapitulate cardiac sodium channel function remains unclear.133 134 Transcripts for accessory calcium channel 2-
and ß-subunits have been identified in rabbit heart and probably are present in human heart.
Abnormalities That Might Underlie Other Forms of LQTS
Defects in KVLQT1, HERG, and SCN5A probably account for >90% of identified cases of LQTS. It seems reasonable that defects in other genes encoding cardiac ion channels will be identified as the cause of LQTS linked to other loci. These could be defects in channels or pumps responsible for inward current or those responsible for outward currents, as described above. It is also conceivable that abnormalities in genes involved in the regulation of ion channel expression might be defective; one possibility discussed below is defect(s) in sympathetically mediated expression of ion channel or other genes. Precedents in the study of other genetic diseases involving the cardiovascular system provide some direction in this regard. For example, defects in a number of genes encoding elements of the cardiac sarcomere can produce the hypertrophic cardiomyopathy phenotype.135 136 By analogy, mutations in any one of a number of proteins whose normal function determines the AP may produce the LQTS phenotype. In hypertrophic cardiomyopathy, it is now recognized that some mutations carry a much graver prognosis than others.137 This finding not only has clinical implications for management and genetic testing of patients but also provides a major lead for further studies of basic mechanisms; even the rudimentary current state of knowledge regarding LQTS suggests that similar genetically determined heterogeneity occurs. Another possibility is raised by studies of X-linked muscular dystrophy, in which a wide range of clinical manifestations can be observed with small changes in the mutated gene that encodes a protein called dystrophin.138 In Duchenne muscular dystrophy, severe skeletal myopathy (with or without dilated cardiomyopathy) is observed, whereas in Becker-type muscular dystrophy there is a milder skeletal myopathy (again with or without a dilated cardiomyopathy). A third defect linked to the dystrophin gene is the cardiospecific disorder called X-linked dilated cardiomyopathy. Interestingly, the cardiac defects in Duchenne and Becker-type muscular dystrophy are quite similar to each other, whereas the defect in X-linked dilated cardiomyopathy probably resides in a cardiospecific region of the dystrophin gene. Thus, subtly different mutations in a single gene may cause very dramatic differences in the clinical phenotype. Importantly, the function of dystrophin (which now appears to play a role in cytoskeletal support) was unknown when mutations in the gene were identified in muscular dystrophy.139 Consequently, it must be recognized that merely identifying the disease-causing gene, especially a novel gene, does not guarantee unlocking the secrets behind the mechanism of disease. In LQTS, therefore, it should not be completely surprising that, even after new gene defects are identified, the mechanisms producing the disease may still remain something of a mystery.
Importantly, not all of the clinical manifestations of LQTS need be attributable directly to the mutant gene product. As discussed above, in a highly integrated system such as the AP, abnormalities in any single element may then cause abnormal function of other (genetically normal) elements. For example, delayed repolarization by either defective inactivation of channels carrying inward current (eg, SCN5A in LQT3) or defective function of a potassium channel carrying outward current (eg, HERG in LQT2) may prolong APs sufficiently to allow normally inactivating currents such as ICa-L to reactivate and cause EADs and/or triggering.50 In addition, it is conceivable that compensatory changes in expression of other genes might come into play in the long-term control of the AP. For example, prolonged APs in other situations (eg, during treatment with AP-prolonging drugs) increase contractility, possibly by increasing intracellular calcium.140 Such increases, were they to be maintained, might not only promote arrhythmogenesis but also influence transcription of a variety of other genes to affect the phenotype observed clinically.
Adrenergic Dependence of LQTS
The adrenergic dependence of arrhythmias in LQTS must now be interpreted in the context of new molecular genetic information. Adrenergic stimulation can modify repolarization and produce arrhythmias in normal subjects and those with LQTS in a number of ways. First, ß-adrenergic stimulation directly increases the magnitude of ICa-L, of the pacemaker current If, and of the repolarizing currents IKs and ICl-cAMP. The usual result is an increase in heart rate with AP shortening, presumably reflecting a greater increase in IKs and ICl-cAMP than in ICa-L. A defect in any of these important AP control mechanisms (eg, defective response of IKs or ICl-cAMP or enhanced response of ICa-L) might well account for the clinical feature that some patients with LQTS "fail to shorten" their QT interval appropriately with adrenergic stimulation, eg, during exercise. Alternatively, the response of mutant KVLQT1-, HERG-, or SCN5A-encoded channels to adrenergic stimulation may prove to be abnormal in LQTS. Second, in experimental situations in which cardiac APs are prolonged and EADs (but no triggering) are present, addition of sympathetic stimulation can be sufficient to elicit triggering.141 Thus, patients with LQTS may be particularly vulnerable to sympathetically mediated arrhythmias with even normal levels of sympathetic tone. Third, an increase in APD by a variety of mechanisms increases contractility, possibly by increasing intracellular calcium.140 A number of studies suggest that cells with increased intracellular calcium may be especially susceptible to the development of abnormal automaticity.131 142 143 Finally, it remains conceivable that as-yet-unidentified gene defects in LQTS could involve molecules important for cardiac sympathetic innervation or that the described ion channel defects result in secondary changes in the number or function of such molecules. In addition, abnormalities of distribution of the sympathetic nerves to the heart could contribute to alterations in ion channel function, since a number of studies now indicate that expression of some ion channel genes, including those encoding calcium and potassium channels, can be modulated by sympathetic activity,144 145 and abnormalities in cardiac sympathetic innervation in experimental animals can produce QT prolongation.146 147 148
|
Current Understanding of the Pathophysiology of LQTS and Unanswered Questions |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
Cardiac repolarization represents a delicate balance between inward and outward currents during the plateau phase of the cardiac AP. Either persistent inward current (eg, through sodium channels) or reduced outward current (eg, through the channels responsible for IKr) can cause the LQTS phenotype. AP prolongation then results in EADs that can induce the characteristic arrhythmia, torsades de pointes. The extent to which these cellular abnormalities can be attributed directly to changes in INa, IKr, or the channel encoded by KVLQT1 or indirectly to secondary changes in other currents, such as L-type calcium current or sodium-calcium exchange, requires further study, as do the mechanisms that confer sensitivity to adrenergic stimuli. The mechanisms underlying torsades de pointes are uncertain: possibilities include triggered activity arising from EADs or heterogeneity in repolarization (resulting from the presence of EADs in some regions of the heart and not in others) that facilitates reentrant excitation. Either mechanism appears most likely to result from EADs developing primarily in critical regions of the heart, such as the conducting system or M cells. Interestingly, IKr in M cells is similar to that in endocardium and epicardium, but IKs is reduced.149 It is increasingly recognized that ion currents display such regional heterogeneity even under physiological conditions.150 151 152 153 The resultant heterogeneity in APDs may play a key role in determining the ECG manifestations of individual gene defects and in the development of torsades de pointes and other arrhythmias.58
Since not all the molecular defects in LQTS have been identified, it is still conceivable that mutations in critical genes in the sympathetic receptor-effector apparatus may be responsible for adrenergic sensitivity in some subsets. Alternatively, the typical sensitivity to adrenergic stimuli displayed by patients with LQTS may reflect an abnormal response to normal sympathetic activity and innervation. Such an abnormal response to sympathetic activity may be related to increased intracellular calcium, probably a common finding in LQTS.
Many areas of research are opened up by the exciting new molecular genetic findings in LQTS. Examples include studies of the basic biophysics of the normal and mutant KVLQT1, SCN5A, and HERG gene products; studies to identify drug therapies that might correct the defects in these mutations; and studies to determine the relationships between clinical phenotypes and underlying genetic defects.18 26 36 37 38 88 101 The extent to which activation of intracellular signaling systems (as occurs during adrenergic stress) alters the function of these channels is unknown. Similarly, the mechanisms whereby abnormalities in SCN5A or HERG cause sinus bradycardia in LQTS remain to be explored. The HERG gene was originally cloned from a human hippocampal cDNA library, and mRNA transcripts encoding the murine homologue have been reported in extracardiac tissues such as brain and liver.154 It will be interesting to determine the role of HERG at these sites. Since it is now known that defects in sodium current or in IKr can produce abnormally long APs, it is reasonable to ask whether other diseases in which APs are abnormally prolonged (and in which abnormally long APs have been linked to arrhythmogenesis) might have a similar basis. The most obvious example is in patients with drug-associated LQTS: does a subset of such patients carry subclinical mutations in SCN5A or in HERG that are manifest upon only challenge with AP-prolonging drugs? Abnormally long APs have also been linked to arrhythmias in patients with dilated cardiomyopathy155 156 and hypertension.157 It will be interesting to determine the extent of the role of abnormalities in the regulatory or coding regions of KVLQT1, HERG, SCN5A, or other genes whose products are involved in repolarization. It seems likely that long-standing abnormalities in AP control in LQTS result in other changes in cellular homeostasis: for example, is the expression of other channels increased or are the control mechanisms for intracellular calcium abnormal? These questions may be best addressed in animal models in which mutant LQTS genes are expressed instead of or along with normal ones. The suggestion from in vitro studies that different mutations in the same gene may produce a spectrum of clinical phenotypes will need to be investigated. Preliminary data suggest a role for sodium channel blockers such as mexiletine in LQT3, linked to late-opening sodium channels.26 37 In patients with this defect, blockers of the late-opening sodium channels might entirely reverse all the manifestations of the syndrome. Use of sodium channel blockers in patients with other defects might theoretically also shorten the QT interval by reducing inward current during the plateau34 ; however, they would not be expected to reverse the ion channel defect underlying the syndrome. In patients with LQTS due to abnormal potassium channel function, therapies directed at altering the function of the abnormal channels to increase outward current (eg, potassium channel openers) might achieve the latter effect. While these are tantalizing suggestions for future therapy after evaluation in vitro and in controlled clinical trials, ß-blockers still remain the mainstay of therapy.
The multiplicity of defects that have already been identified as causing LQTS and the fact that loci remain to be identified and characterized make routine genetic testing for the disease impractical at this time. At this point, presymptomatic diagnosis is possible for family members of those patients in whom the molecular basis of the defect has been characterized. If the identification of specific defects turns out to be important for therapy or for prognosis, then genetic testing may assume an important clinical role.
A major mechanism of action of many drugs that cause torsades de pointes is IKr block. On the basis of the identification of mutations in HERG as a cause of LQTS, one might well ask whether block of IKr is a suitable or desirable target for antiarrhythmic intervention. The effects of drugs that, at clinically useful dosages, reduce IKr by 50% would be predicted to be similar to those of HERG mutations that result in no functional IKr channels and that display no dominant negative effect (eg, 1261). Alternatively, drugs that rapidly produce IKr block during the plateau of the AP and whose block equally rapidly dissipates at the end of the plateau might still be antiarrhythmic, particularly in the diseased heart. Compounds that delay sodium channel inactivation have been developed as positive inotropic drugs.158 One mechanism is thought to be increased sodium loading, with resultant increased sodium-calcium exchange. On the basis of the finding that abnormalities in SCN5A cause LQTS, it will be interesting to see whether the beneficial effect of interfering with sodium channel inactivation might be outweighed by its proarrhythmic potential.
AP prolongation is well established in animal models as an effective antiarrhythmic intervention. A major liability is the development of torsades de pointes. One implication of the molecular data now available from studies of LQTS is that block of IKr or interference with inactivation of INa is not likely to be the most desirable strategy to achieve this effect. Rather, the identification of multiple ion channels active during repolarization raises the possibility that targets for drug action can be identified that achieve a desired antiarrhythmic effect without causing torsades de pointes.
The identification of lesions in KVLQT1, HERG, and SCN5A has already resulted in a dramatic increase in our understanding of the basic pathogenesis of LQTS and in the development of lines of research that will have important implications not only for LQTS but also for other disease states in which control of the cardiac AP is an important consideration. The identification of these and other mutations in LQTS therefore represents an exciting beginning to studies in which clinical arrhythmia syndromes will be related to their fundamental molecular and cellular mechanisms.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Footnotes |
|---|
Reprint requests to G. Michael Vincent, MD, Department of Medicine, LDS Hospital, Eighth Ave and C St, Salt Lake City, UT 84143-0001.
This article summarizes the outcome of a workshop sponsored and funded by the Sudden Arrhythmic Death Syndromes (SADS) Foundation, January 7-9, 1995. The need for the workshop was proposed by Peter J. Schwartz, MD (University of Pavia, Italy) and G. Michael Vincent, MD (LDS Hospital, Salt Lake City, Utah); Dr Schwartz acted as chairman. Other participants were Charles Antzelevitch, PhD (Masonic Medical Research Laboratory, Utica, NY); Arthur M. Brown, MD, PhD (MetroHealth Medical Center, Cleveland, Ohio); Thomas J. Colatsky, PhD (Wyeth-Ayerst Research, Princeton, NJ); Richard S. Crampton, MD (University of Virginia, Charlottesville, Va); Robert S. Kass, PhD (University of Rochester, Rochester, NY); Ralph Lazzara, MD (University of Oklahoma, Oklahoma City, Okla); Arthur J. Moss, MD (University of Rochester, Rochester, NY); Dan M. Roden, MD (Vanderbilt University, Nashville, Tenn); Michael R. Rosen, MD (Columbia University, New York City, NY); Michael C. Sanguinetti, PhD (University of Utah, Salt Lake City, Utah); Jeffrey A. Towbin, MD (Baylor College of Medicine, Houston, Tex); and Douglas P. Zipes, MD (University of Indiana, Indianapolis, Ind). Members of the writing committee were Drs Lazzara, Roden, Rosen, Schwartz, and Vincent. The final preparation and organization of the manuscript were the responsibility of Dr Roden.
Received January 29, 1996; revision received April 19, 1996; accepted April 23, 1996.
|
References |
|---|
|
TopAbstractIntroductionBackgroundMechanisms Underlying LQTSChromosomal Defects in LQTSCurrent Understanding of the...References |
|---|
1. Schwartz PJ, Periti M, Malliani A. The long QT syndrome. Am Heart J. 1975;89:378-390.[Medline] [Order article via Infotrieve]
2. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59-68.[Medline] [Order article via Infotrieve]
3. Levine SA, Woodworth CR. Congenital deaf-mutism, prolonged QT interval, syncopal attacks and sudden death. N Engl J Med. 1958;259:412-417.
4. Fraser GR, Froggatt P, Murphy T. Genetical aspects of the cardio-auditory syndrome of Jervell and Lange-Nielsen (congenital deafness and electrocardiographic abnormalities). Ann Hum Genet. 1964;28:133-156.[Medline] [Order article via Infotrieve]
5. Romano C, Gemme G, Pongiglione R. Aritmie cardiache rare in eta pediatrica. Clin Pediatr. 1963;45:656-683.
6. Ward OC. A new familial cardiac syndrome in children. J Irish Med Assoc. 1964;54:103-106.[Medline] [Order article via Infotrieve]
7. Schwartz PJ. Idiopathic long QT syndrome: progress and questions. Am Heart J. 1985;109:399-411.[Medline] [Order article via Infotrieve]
8.
Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation. 1993;88:782-784.
9. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur. 1966;59:263-272.
10. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992;327:846-852.[Abstract]
11.
Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati EH, MacCluer J, Hall WJ, Weitkamp L, Vincent GM, Garson A Jr, Robinson JL, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation. 1991;84:1136-1144.
12. Hashiba K. Hereditary QT prolongation syndrome in Japan: genetic analysis and pathological findings of the conducting system. Jpn Circ J. 1978;42:1133-1150.[Medline] [Order article via Infotrieve]
13. Hashiba K. Sex differences in phenotypic manifestation and gene transmission in the Romano-Ward syndrome. Ann N Y Acad Sci. 1992;644:142-156.[Medline] [Order article via Infotrieve]
14.
Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
15.
De Ambroggi L, Bertoni T, Locati E, Stramba-Badiale M, Schwartz PJ. Mapping of body surface potentials in patients with the idiopathic long QT syndrome. Circulation. 1986;74:1334-1345.
16.
Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval: a marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation. 1994;89:1681-1689.
17. Malfatto G, Beria G, Sala S, Bonazzi O, Schwartz PJ. Quantitative analysis of T wave abnormalities and their prognostic implications in the idiopathic long QT syndrome. J Am Coll Cardiol. 1994;23:296-301.[Abstract]
18.
Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, Vincent GM, Lehmann MH, Keating MT, MacCluer JW, Timothy KW. ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:2929-2934.
19.
Nador F, Beria G, De Ferrari GM, Stramba-Badiale M, Locati EH, Lotto A, Schwartz PJ. Unsuspected echocardiographic abnormality in the long QT syndrome: diagnostic, prognostic, and pathogenetic implications. Circulation. 1991;84:1530-1542.
20.
De Ferrari GM, Nador F, Beria G, Sala S, Lotto A, Schwartz PJ. Effect of calcium channel block on the wall motion abnormality of the idiopathic long QT syndrome. Circulation. 1994;89:2126-2132.
21. Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome. Am Heart J. 1975;89:45-50.[Medline] [Order article via Infotrieve]
22. Zareba W, Moss AJ, Le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol. 1994;23:1541-1546.[Abstract]
23.
Crampton RS. Preeminence of left stellate ganglion in the long QT syndrome. Circulation. 1979;59:769-778.
24. Jackman WM, Szabo B, Friday DJ, Margolis PD, Moulton K, Wang X, Patterson E, Lazzara R. Ventricular tachyarrhythmias related to early afterdepolarizations and triggered firing: relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents. J Cardiovasc Electrophysiol. 1990;1:170-195.
25. Shimizu W, Ohe T, Kurita T, Tokuda T, Shimomura K. Epinephrine-induced ventricular premature complexes due to early afterdepolarizations and effects of verapamil and propranolol in a patient with congenital long QT syndrome. J Cardiovasc Electrophysiol. 1994;5:438-444.[Medline] [Order article via Infotrieve]
26.
Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LSK, Colatsky TJ. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate: implications for gene-specific therapy. Circulation. 1995;92:3381-3386.
27. Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971;285:903-904.
28.
Schwartz PJ, Locati EH, Moss AJ, Crampton RS, Trazzi R, Ruberti U. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome: a worldwide report. Circulation. 1991;84:503-511.
29. Eldar M, Griffin JC, Abbott JA, Benditt D, Bhandari A, Herre JM, Benson DW, Scheinman MM. Permanent cardiac pacing in patients with the long QT syndrome. J Am Coll Cardiol. 1987;10:600-607.[Abstract]
30.
Moss AJ, Liu JE, Gottlieb S, Locati EH, Schwartz PJ, Robinson JL. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome. Circulation. 1991;84:1524-1529.
31.
Fish FA, Prakash C, Roden DM. Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. Circulation. 1990;82:1362-1369.
32.
Ben-David J, Zipes DP. Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. Circulation. 1990;82:225-233.
33. Schwartz PJ, Bonazzi O, Locati E, Napolitano C, Sala S. Pathogenesis and therapy of the idiopathic long QT syndrome. Ann N Y Acad Sci. 1992;644:112-141.[Medline] [Order article via Infotrieve]
34. Chezalviel-Guilbert F, Davy JM, Poirier JM, Weissenburger J. Mexiletine antagonizes effects of sotalol on QT interval duration and its proarrhythmic effects in a canine model of torsade de pointes. J Am Coll Cardiol. 1995;26:787-792.[Abstract]
35. Sato T, Hata Y, Yamamoto M, Morita H, Mizuo K, Yamanari H, Saito D, Ohe T. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J Cardiovasc Electrophysiol. 1995;6:279-282.[Medline] [Order article via Infotrieve]
36. Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995;376:683-685.[Medline] [Order article via Infotrieve]
37. Bangalore R, An RH, Kass RS. Molecular pharmacology of an inherited heart disease. Biophys J. 1996;70:A260. Abstract.
38.
Dumaine R, Wang Q, Keating MT, Hartmann HA, Schwartz PJ, Brown AM, Kirsch GE. Multiple mechanisms of Na+ channel-linked long-QT syndrome. Circ Res. 1996;78:916-924.
39.
Priori SG, Napolitano C, Cantu F, Brown AM, Schwartz PJ. Differential response to Na+ channel blockade, beta-adrenergic stimulation and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome. Circ Res. 1996;78:1009-1015.
40. Schwartz PJ, Locati EH, Napolitano C, Priori SG. The long QT syndrome. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1995:788-811.
41. Dangman KH, Hoffman BF. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther. 1981;217:851-862.[Abstract]
42.
Brachmann J, Scherlag BJ, Rosenshtraukh LV, Lazzara R. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia. Circulation. 1983;68:846-856.
43.
Roden DM, Hoffman BF. Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: relationship to potassium and cycle length. Circ Res. 1985;56:857-867.
44.
Strauss HC, Bigger JT, Hoffman BF. Electrophysiological and beta-receptor blocking effects of MJ 1999 on dog and rabbit cardiac tissue. Circ Res. 1970;26:661-678.
45. Brown B. Early afterdepolarizations induced by batrachotoxin: possible involvement of a sodium current. Fed Proc. 1983;42:521. Abstract.
46.
El-Sherif N, Zeiler RH, Craelius W, Gough WB, Henkin R. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Circ Res. 1988;63:286-305.
47.
January CT, Riddle JM, Salata JJ. A model for early afterdepolarizations: induction with the Ca2+ channel agonist Bay K 8644. Circ Res. 1988;62:563-571.
48.
January CT, Riddle JM. Early afterdepolarizations: mechanism of induction and block: a role for L-type Ca2+ current. Circ Res. 1989;64:977-990.
49. Szabo B, Sweidan R, Rajagopalan CB, Lazzara R. Role of Na+:Ca2+ exchange current in Cs+-induced early afterdepolarizations in Purkinje fibers. J Cardiovasc Electrophysiol. 1994;5:933-944.[Medline] [Order article via Infotrieve]
50. Zeng J, Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J. 1995;68:949-964.[Medline] [Order article via Infotrieve]
51. Cinca J, Sassine A, Deceuninck P, Roca J, Gagne P, Morena H, Puech P. The dependence of T wave alternans on diastolic resting period duration. Eur J Cardiol. 1978;7:299-309.[Medline] [Order article via Infotrieve]
52. Franz MR, Swerdlow CD, Liem LB, Schaefer J. Cycle length dependence of human action potential duration in vivo: effects of single extrastimuli, sudden sustained rate acceleration and deceleration, and different steady-state frequencies. J Clin Invest. 1988;82:972-979.
53.
Saitoh H, Bailey JC, Surawicz B. Action potential duration alternans in dog Purkinje and ventricular muscle fibers: further evidence in support of two different mechanisms. Circulation. 1989;80:1421-1431.
54.
Zeng J, Laurita KR, Rosenbaum DS, Rudy Y. Two components of the delayed rectifier K+ current in ventricular myocytes of the guinea pig type: theoretical formulation and their role in repolarization. Circ Res. 1995;77:140-152.
55.
Dilly SG, Lab MJ. Electrophysiological alternans and restitution during acute regional ischaemia in myocardium of anaesthetized pig. J Physiol. 1988;402:315-333.
56.
Sicouri S, Antzelevitch C. A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle: the M cell. Circ Res. 1991;68:1729-1741.
57. Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: the role of M cells in the generation of U waves, triggered activity and torsades de pointes. J Am Coll Cardiol. 1994;23:259-277.[Abstract]
58. Antzelevitch C, Sicouri S, Lukas A, Nesterenko VV, Liu DW, Di Diego JM. Regional differences in the electrophysiology of ventricular cells: physiological and clinical implications. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, Pa: WB Saunders Co; 1995:228-245.
59.
D'Alnoncourt CN, Zierhut W, Luderitz B. `Torsade de pointes' tachycardia: re-entry or focal activity? Br Heart J. 1982;48:213-216.
60. Leichter D, Danilo P Jr, Boyden P, Rosen TS, Rosen MR. A canine model of torsades de pointes. Pacing Clin Electrophysiol. 1988;11:2235-2245.[Medline] [Order article via Infotrieve]
61.
Levine JH, Spear JF, Guarnieri T, Weisfeldt ML, De Langen CDJ, Becker LC, Moore EN. Cesium chloride-induced long QT syndrome: demonstration of afterdepolarizations and triggered activity in vivo. Circulation. 1985;72:1092-1103.
62.
Pertsov AM, Davidenko JM, Salomonsz R, Baxter WT, Jalife J. Spiral waves of excitation underlie reentrant activity in isolated cardiac muscle. Circ Res. 1993;72:631-650.
63.
Gray RA, Jalife J, Panfilov A, Baxter WT, Cabo C, Davidenko JM, Pertsov AM. Nonstationary vortexlike reentrant activity as a mechanism of polymorphic ventricular tachycardia in the isolated rabbit heart. Circulation. 1995;91:2454-2469.
64. Campbell RW, Furniss SS. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Am J Cardiol. 1993;72:80A-85A.[Medline] [Order article via Infotrieve]
65.
Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsade de pointes: disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation. 1992;86:1376-1382.
66. Derakhchan K, Klug D, Bouchard C, Helie F, Pharand C, Sasyniuk BI, Kus T, Cardinal R. Torsades de pointes induced by d-sotalol in canine atrio-ventricular block: initiation in the conduction system followed by spatially unstable reentry. Circulation. 1995;92(suppl I):I-640. Abstract.
67.
Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science. 1991;252:704-706.
68. Yatani A, Okabe K, Polakis P, Halenbeck R, McCormick F, Brown AM. ras p21 GAP inhibit coupling of muscarinic receptors to atrial K+ channels. Cell. 1990;61:769-776.[Medline] [Order article via Infotrieve]
69. Roy N, Kahlem P, Dausse E, Bennaceur M, Faure S, Weissenbach M, Komajda M, Denjoy I, Coumel P, Schwartz K, Guicheney P. Exclusion of Hras from the long QT locus. Nat Genet. 1994;8:113-114.[Medline] [Order article via Infotrieve]
70. Russell MW, Brody LC, Munroe D, Dick MI, Collins FS. Characterization of a recombination event excluding the Harvey-ras-1 (H-ras-1) locus in a Romano-Ward long QT syndrome family linked to chromosome 11p15 and isolation of a polymorphic repeat teleomeric to H-ras-1. Am J Hum Genet. 1994;55:A353. Abstract.
71. Schwartz K. On the pulse of genetic cardiology. Nature. 1994;8:110-111.
72. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996;12:17-23.[Medline] [Order article via Infotrieve]
73. Keating M, Dunn C, Atkinson D, Timothy K, Vincent GM, Leppert M. Consistent linkage of the long-QT syndrome to the Harvey ras-I locus on chromosome 11. Am J Hum Genet. 1991;49:1335-1339.[Medline] [Order article via Infotrieve]
74. Towbin JA, Pagotta L, Siu B, Robinson J, Moss A, McCabe ERB, Hejtmancik JF. Romano-Ward long QT syndrome: evidence of genetic heterogeneity. Pediatr Res. 1992;31:23A. Abstract.
75.
Benhorin J, Kalman YM, Medina A, Towbin J, Rave-Harel N, Dyer TD, Blangero J, MacCluer JW, Kerem BS. Evidence of genetic heterogeneity in the long QT syndrome. Science. 1993;260:1960-1962.
76. Curran M, Atkinson D, Timothy K, Vincent GM, Moss AJ, Leppert M, Keating M. Locus heterogeneity of autosomal dominant long QT syndrome. J Clin Invest. 1993;92:799-803.
77.
Dean JC, Cross S, Jennings K. Evidence of genetic and phenotypic heterogeneity in the Romano-Ward syndrome. J Med Genet. 1993;30:947-950.
78. Akimoto K, Matsuoka R, Kasanuki H, Takao A, Monma K, Hayakawa K, Hosoda S. Linkage analysis in a Japanese long QT syndrome family. Kokyuto Junkan—Respir Circ. 1993;41:463-465.
79.
Towbin JA, Li H, Taggart RT, Lehmann MH, Schwartz PJ, Satler CA, Ayyagari R, Robinson JL, Moss AJ, Hejtmancik JF. Evidence of genetic heterogeneity in Romano-Ward long QT syndrome: analysis of 23 families. Circulation. 1994;90:2635-2644.
80. Jiang C, Atkinson D, Towbin JA, Splawski I, Lehmann MH, Li H, Timothy K, Taggart RT, Schwartz PJ, Vincent GM, Moss AJ, Keating MT. Two long QT syndrome loci map to chromosomes 3 and 7 with evidence for further heterogeneity. Nat Genet. 1994;8:141-147.[Medline] [Order article via Infotrieve]
81. Schott JJ, Charpentier F, Peltier S, Foley P, Drouin E, Bouhour JB, Donnelly P, Vergnaud G, Bachner L, Moisan JP, Le Marec H, Pascal O. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet. 1995;57:1114-1122.[Medline] [Order article via Infotrieve]
82. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80:795-803.[Medline] [Order article via Infotrieve]
82.
Benson DW, MacRae CA, Vesely MR, Walsh EP, Seidman JG, Seidman CE, Satler CA. Missense mutation in the pore region of HERG causes familial long QT syndrome. Circulation. 1996;93:1791-1795.
83. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL, Moss AJ, Towbin JA, Keating MT. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995;80:805-811.[Medline] [Order article via Infotrieve]
84.
Papazian DM, Schwarz TL, Tempel BL, Jan YN, Jan LY. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science. 1987;237:749-753.
85. Tamkun MM, Knoth KM, Walbridge JA, Kroemer H, Roden DM, Glover DM. Molecular cloning and characterization of two voltage-gated K+ channel cDNAs from human ventricle. FASEB J. 1991;5:331-337.[Abstract]
86.
Warmke J, Drysdale R, Ganetzky B. A distinct potassium channel polypeptide encoded by the Drosophila eag locus. Science. 1991;252:1560-1562.
87.
Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A. 1994;91:3438-3442.
88. Sanguinetti MC, Jiang C, Curran ME, Keating MT. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995;81:299-307.[Medline] [Order article via Infotrieve]
89.
Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269:92-95.
90.
Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K+ current: differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990;96:195-215.
91.
Spector PS, Curran ME, Keating MT, Sanguinetti MC. Class III antiarrhythmic drugs block HERG, a human delayed rectifier K+ channel: open channel block by methanesulfonanilides. Circ Res. 1996;78:499-503.
92. Sanguinetti MC, Jurkiewicz NK. Role of external Ca2+ and K+ in gating of cardiac delayed rectifier K+ currents. Pflugers Arch. 1992;420:180-186.[Medline] [Order article via Infotrieve]
93.
Yang T, Roden DM. Extracellular potassium modulation of drug block of IKr: implications for torsades de pointes and reverse use-dependence. Circulation. 1996;93:407-411.
93. Compton SJ, Lux RL, Ramsay MR, Strelich KT, Sanguinetti MC, Keating MT, Mason JW. Gene-derived therapy in inherited long QT syndrome: correction of abnormal repolarization by potassium. Pacing Clin Electrophysiol. 1996;19:642. Abstract.
94.
Colatsky TJ, Follmer CH, Starmer CF. Channel specificity in antiarrhythmic drug action: mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias. Circulation. 1990;82:2235-2242.
95.
Sanguinetti MC, Jurkiewicz NK, Scott A, Siegl PKS. Isoproterenol antagonizes prolongation of refractory period by the class III antiarrhythmic agent E-4031 in guinea pig myocytes: mechanism of action. Circ Res. 1991;68:77-84.
96. Miller C. Annus mirabilis of potassium channels. Science. 1990;252:1092-1096.
97. MacKinnon R. Determination of the subunit stoichiometry of a voltage-activated potassium channel. Nature. 1991;350:232-235.[Medline] [Order article via Infotrieve]
98.
England SK, Uebele VN, Shear H, Kodali J, Bennett PB, Tamkun MM. Characterization of a voltage-gated K+ channel beta subunit expressed in human heart. Proc Natl Acad Sci U S A. 1995;92:6309-6313.
99.
Morales MJ, Castellino RC, Crews AL, Rasmusson RL, Strauss HC. A novel ß subunit increases rate of inactivation of specific voltage-gated potassium channel subunits. J Biol Chem. 1995;270:6272-6277.
100. Majumder K, De Biasi M, Wang Z, Wible BA. Molecular cloning and functional expression of a novel potassium channel beta-subunit from human atrium. FEBS Lett. 1995;361:13-16.[Medline] [Order article via Infotrieve]
101.
Sanguinetti MC, Curran ME, Spector PS, Keating MT. Spectrum of HERG K+ channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A. 1996;93:2208-2212.
102. Roden DM. Current status of class III antiarrhythmic therapy. Am J Cardiol. 1993;72:44B-49B.[Medline] [Order article via Infotrieve]
103. Echt DS, Lee JT, Murray KT, Vorperian V, Borganelli SM, Crawford DM, Friedrich T, Roden DM. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J Cardiovasc Electrophysiol. 1995;6:687-699.[Medline] [Order article via Infotrieve]
104. Wiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI. Torsades de pointes with almokalant, a new class III antiarrhythmic drug. Am Heart J. 1993;126:1008-1011.[Medline] [Order article via Infotrieve]
105.
Wang Z, Fermini B, Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J Pharmacol Exp Ther. 1995;272:184-196.
106.
Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther. 1985;232:817-825.
107.
Lee KS. Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells. J Pharmacol Exp Ther. 1992;262:99-108.
108.
Yang T, Snyders DJ, Roden DM. Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed rectifier K+ current (IKr) in AT-1 cells: concentration-, time-, voltage-, and use-dependent effects. Circulation. 1995;91:1799-1806.
109. Locati EH, Maison-Blanche P, Dejode P, Cauchemez B, Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol. 1995;25:1564-1575.[Abstract]
110. Kubo Y, Reuveny E, Slesinger PA, Jan YN, Jan LY. Primary structure and functional expression of a rat G-protein-coupled muscarinic potassium channel. Nature. 1993;364:802-806.[Medline] [Order article via Infotrieve]
111. Ho K, Nichols CG, Lederer WJ, Lytton J, Vassilev PM, Kanazirska MV, Hebert SC. Cloning and expression of an inwardly rectifying ATP-regulated potassium channel. Nature. 1993;362:31-38.[Medline] [Order article via Infotrieve]
112.
Wible BA, De Biasi M, Majumder K, Taglialatela M, Brown AM. Cloning and functional expression of an inwardly rectifying K+ channel from human atrium. Circ Res. 1995;76:343-350.
113. Krapivinsky G, Gordon EA, Wickman K, Velimirovic B, Krapivinsky L, Clapham DE. The G-protein-gated atrial K+ channel IKACh is a heteromultimer of two inwardly rectifying K+-channel proteins. Nature. 1995;374:135-141.[Medline] [Order article via Infotrieve]
114.
Takumi T, Ohkubo H, Nakanishi S. Cloning of a membrane protein that induces a slow voltage-gated potassium current. Science. 1988;242:1042-1045.
115.
Folander K, Smith JS, Antanavage J, Bennett C, Stein RB, Swanson R. Cloning and expression of the delayed rectifier IsK channel from neonatal rat heart and diethylstilbestrol-primed rat uterus. Proc Natl Acad Sci U S A. 1990;87:2975-2979.
116. Honore E, Attali B, Romey G, Heurteaux C, Ricard P, Lesage F, Lazdunski M, Barhanin J. Cloning, expression, pharmacology and regulation of a delayed rectifier K+ channel in mouse heart. EMBO J. 1991;10:2805-2811.[Medline] [Order article via Infotrieve]
117. Attali B, Guillemare E, Lesage F, Honore E, Romey G, Lazdunski M, Barhanin J. The protein IsK is a dual activator of K+ and Cl- channels. Nature. 1993;365:850-852.[Medline] [Order article via Infotrieve]
118.
Yang T, Kupershmidt S, Roden DM. Anti-minK antisense decreases the amplitude of the rapidly-activating cardiac delayed rectifier K+ current. Circ Res. 1995;77:1246-1253.
119. Yue DT, Marban E. A novel cardiac potassium channel that is active and conductive at depolarized potentials. Pflugers Arch. 1988;413:127-133.[Medline] [Order article via Infotrieve]
120.
Hume JR, Harvey RD. Chloride conductance pathways in heart. Am J Physiol. 1991;261:C399-C412.
121. Jentsch TJ, Gunther W, Pusch M, Schwappach B. Properties of voltage-gated chloride channels of the ClC gene family. J Physiol. 1995;482:19S-25S.
122.
Levesque PC, Hart PJ, Hume JR, Kenyon JL, Horowitz B. Expression of cystic fibrosis transmembrane regulator Cl- channels in heart. Circ Res. 1992;71:1002-1007.
123.
Van Wagoner DR. Mechanosensitive gating of atrial ATP-sensitive potassium channels. Circ Res. 1993;72:973-983.
124. Weiss JN, Nademanee K, Stevenson WG, Singh B. Ventricular arrhythmias in ischemic heart disease. Ann Intern Med. 1991;114:784-797.
125. Weiss JN, Venkatesh N. Metabolic regulation of cardiac ATP-sensitive K+ channels. Cardiovasc Drugs Ther. 1993;7(suppl 3):499-505.
126. Sanguinetti MC. Na+-activated and ATP-sensitive K+ channels in the heart. Prog Clin Biol Res. 1990;334:85-109.[Medline] [Order article via Infotrieve]
127.
Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995;4:1603-1607.
128.
West JW, Patton DE, Scheuer T, Wang Y, Goldin AL, Catterall WA. A cluster of hydrophobic amino acid residues required for fast Na(+)-channel inactivation. Proc Natl Acad Sci U S A. 1992;89:10910-10914.
129.
Hartmann HA, Tiedeman AA, Chen SF, Brown AM, Kirsch GE. Effects of III-IV linker mutations on human heart Na+ channel inactivation gating. Circ Res. 1994;75:114-122.
130.
El-Sherif N, Fozzard HA, Hanck DA. Dose-dependent modulation of the cardiac sodium channel by sea anemone toxin ATXII. Circ Res. 1992;70:285-301.
131.
Thandroyen FT, Morris AC, Hagler HK, Ziman B, Pai L, Willerson JT, Buja LM. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res. 1991;69:810-819.
132.
Isom LL, De Jongh KS, Patton DE, Reber BFX, Offord J, Charbonneau H, Walsh K, Goldin AL, Catterall WA. Primary structure and functional expression of the ß1 subunit of the rat brain sodium channel. Science. 1992;256:839-842.
133.
Makita N, Bennett PB Jr, George AL Jr. Voltage-gated Na+ channel ß1 subunit mRNA expressed in adult human skeletal muscle, heart, and brain is encoded by a single gene. J Biol Chem. 1994;269:7571-7578.
134.
Nuss HB, Chiamvimonvat N, Perez-Garcia MT, Tomaselli GF, Marban E. Functional association of the ß1 subunit with human cardiac (hH1) and rat skeletal muscle (µ1) sodium channel subunits expressed in Xenopus oocytes. J Gen Physiol. 1995;106:1171-1191.
135.
Marian AJ, Roberts R. Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation. 1995;92:1336-1347.
136. Watkins H, Seidman JG, Seidman CE. Familial hypertrophic cardiomyopathy: a genetic model of cardiac hypertrophy. Hum Mol Genet. 1995;4:1721-1727.[Abstract]
137. Watkins H, Rosenzweig A, Hwang DS, Levi T, McKenna W, Seidman CE, Seidman JG. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med. 1992;326:1108-1114.[Abstract]
138. Ahn AH, Kunkel LM. The structural and functional diversity of dystrophin. Nat Genet. 1993;3:283-291.[Medline] [Order article via Infotrieve]
139. Matsumura K, Campbell KP. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve. 1994;17:2-15.[Medline] [Order article via Infotrieve]
140. Wallace AA, Stupienski RF III, Brookes LM, Selnick HG, Claremon DA, Lynch JJ Jr. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J Cardiovasc Pharmacol. 1991;18:687-695.[Medline] [Order article via Infotrieve]
141. Campbell RM, Woosley RL, Iansmith DH, Roden DM. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine. Pacing Clin Electrophysiol. 1990;13:30-36.[Medline] [Order article via Infotrieve]
142.
Di Diego JM, Antzelevitch C. High [Ca2+]o-induced electrical heterogeneity and extrasystolic activity in isolated canine ventricular epicardium. Circulation. 1994;89:1839-1850.
143.
Kihara Y, Morgan JP. Intracellular calcium and ventricular fibrillation: studies in the aequorin-loaded isovolumic ferret heart. Circ Res. 1991;68:1378-1389.
144. Ogawa S, Barnett JV, Sen L, Galper JB, Smith TW, Marsh JD. Direct contact between sympathetic neurons and rat cardiac myocytes in vitro increases expression of functional calcium channels. J Clin Invest. 1992;89:1085-1093.
145. Amlicke JD, Picklo M, Schmidt D, Robertson D, Roden DM. QT prolongation in a new model of sympathetic inhibition. Circulation. 1994;90(suppl I):I-518. Abstract.
146.
Malfatto G, Rosen TS, Steinberg SF, Ursell PC, Sun LS, Daniel S, Danilo P Jr, Rosen MR. Sympathetic neural modulation of cardiac impulse initiation and repolarization in the newborn rat. Circ Res. 1990;66:427-437.
147. Christiansen JL, Stadt HA, Mulroy MJ, Kirby ML. Electrocardiographic QT prolongation after ablation of the nodose placode in the chick embryo: a developmental model of the idiopathic long QT syndrome. Pediatr Res. 1989;26:11-15.[Medline] [Order article via Infotrieve]
148.
Stramba-Badiale M, Lazzarotti M, Schwartz PJ. Development of cardiac innervation, ventricular fibrillation, and sudden infant death syndrome. Am J Physiol. 1992;263:H1514-H1522.
149.
Liu DW, Antzelevitch C. Characteristics of the delayed rectifier current (IKr and IKs) in canine ventricular epicardial, midmyocardial, and endocardial myocytes: a weaker IKs contributes to the longer action potential of the M cell. Circ Res. 1995;76:351-365.
150.
Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res. 1988;62:116-126.
151.
Furukawa T, Kimura S, Furukawa N, Bassett AL, Myerburg RJ. Potassium rectifier currents differ in myocytes of endocardial and epicardial origin. Circ Res. 1992;70:91-103.
152.
Wang Z, Fermini B, Nattel S. Repolarization differences between guinea pig atrial endocardium and epicardium: evidence for a role of ITO. Am J Physiol. 1991;260:H1501-H1506.
153.
Nabauer M, Beuckelmann DJ, Uberfuhr P, Steinbeck G. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation. 1996;93:168-177.
154. Kupershmidt S, Kim R, Roden D. Tissue and species distribution of mRNA encoding erg, an IKr subunit. Circulation. 1995;92(suppl I):I-373. Abstract.
155.
Beuckelmann D, Nabauer M, Erdmann E. Alterations of K+ currents in isolated human ventricular myocytes from patients with terminal heart failure. Circ Res. 1993;73:379-385.
156.
Tomaselli GF, Beuckelmann DJ, Calkins HG, Berger RD, Kessler PD, Lawrence JH, Kass D, Feldman AM, Marban E. Sudden cardiac death in heart failure: the role of abnormal repolarization. Circulation. 1994;90:2534-2539.
157. Aronson RS. Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol. 1991;2:249-261.
158. Doggrell S, Hoey A, Brown L. Ion channel modulators as potential positive inotropic compound for treatment of heart failure. Clin Exp Pharmacol Physiol. 1994;21:833-843.[Medline] [Order article via Infotrieve]
159.
Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation. 1991;84:1831-1851.
160. Roden DM, George AL Jr, Bennett PB. Recent advances in understanding the molecular mechanisms of the long QT syndrome. J Cardiovasc Electrophysiol. 1995;6:1023-1031.[Medline] [Order article via Infotrieve]
161. George AL Jr, Varkony TA, Drabkin HA, Han J, Knops JF, Finley WH, Brown GB, Ward DC, Haas M. Assignment of the human heart tetrodotoxin-resistant voltage-gated Na+ channel alpha-subunit gene (SCN5A) to band 3p21. Cytogenet Cell Genet. 1995;68:67-70.[Medline] [Order article via Infotrieve]
162. Powers PA, Gregg RG, Hogan K. Linkage mapping of the human gene for the alpha 1 subunit of the cardiac DHP-sensitive Ca2+ channel (CACNL1A1) to chromosome 12p13.2-pter using a dinucleotide repeat. Genomics. 1992;14:206-207.[Medline] [Order article via Infotrieve]
163. Stoffel M, Espinosa R III, Powell KL, Philipson LH, Le Beau MM, Bell GI. Human G-protein-coupled inwardly rectifying potassium channel (GIRK1) gene (KCNJ3): localization to chromosome 2 and identification of a simple tandem repeat polymorphism. Genomics. 1994;21:254-256.[Medline] [Order article via Infotrieve]
164. Wymore RS, Korenberg JR, Kinoshita KD, Aiyar J, Coyne C, Chen XN, Hustad CM, Copeland NG, Gutman GA, Jenkins NA, Chandy KG. Genomic organization, nucleotide sequence, biophysical properties, and localization of the voltage-gated K+ channel gene KCNA4/Kv1.4 to mouse chromosome 2/human 11p14 and mapping of KCNC1/Kv3.1 to mouse 7/human 11p14.3-p15.2 and KCNA1/Kv1.1 to human 12p13. Genomics. 1994;20:191-202.[Medline] [Order article via Infotrieve]
165.
Grissmer S, Dethlefs B, Wasmuth JJ, Goldin AL, Gutman GA, Cahalan MD, Chandy KG. Expression and chromosomal localization of a lymphocyte K+ channel gene. Proc Natl Acad Sci U S A. 1990;87:9411-9415.
166. Chevillard C, Attali B, Lesage F, Fontes M, Barhanin J, Lazdunski M, Mattei MG. Localization of a potassium channel gene (KCNE1) to 21q22.1-q22.2 by in situ hybridization and somatic cell hybridization. Genomics. 1993;15:243-245.[Medline] [Order article via Infotrieve]
167. Wainwright BJ, Scambler PJ, Schmidtke J, Watson EA, Law HY, Farrall M, Cooke HJ, Eiberg H, Williamson R. Localization of cystic fibrosis locus to human chromosome 7cen-q22. Nature. 1985;318:384-385.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  W. H. Thiel, B. Chen, T. J. Hund, O. M. Koval, A. Purohit, L.-S. Song, P. J. Mohler, and M. E. Anderson Proarrhythmic Defects in Timothy Syndrome Require Calmodulin Kinase II Circulation, November 25, 2008; 118(22): 2225 - 2234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gao, Q. Xiong, H. Sun, and M. Li Desensitization of Chemical Activation by Auxiliary Subunits: CONVERGENCE OF MOLECULAR DETERMINANTS CRITICAL FOR AUGMENTING KCNQ1 POTASSIUM CHANNELS J. Biol. Chem., August 15, 2008; 283(33): 22649 - 22658. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Burashnikov, W. Shimizu, and C. Antzelevitch Fever Accentuates Transmural Dispersion of Repolarization and Facilitates Development of Early Afterdepolarizations and Torsade de Pointes Under Long-QT Conditions Circ Arrhythm Electrophysiol, August 1, 2008; 1(3): 202 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chinushi, D. Izumi, K. Iijima, S. Ahara, S. Komura, H. Furushima, Y. Hosaka, and Y. Aizawa Antiarrhythmic vs. pro-arrhythmic effects depending on the intensity of adrenergic stimulation in a canine anthopleurin-A model of type-3 long QT syndrome Europace, February 1, 2008; 10(2): 249 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Stehr, T. Christ, B. Rasche, S. Rasche, E. Wettwer, A. Deussen, U. Ravens, T. Koch, and M. Hubler The Effects of Levosimendan on Myocardial Function in Ropivacaine Toxicity in Isolated Guinea Pig Heart Preparations Anesth. Analg., September 1, 2007; 105(3): 641 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rocchetti, V. Freli, V. Perego, C. Altomare, G. Mostacciuolo, and A. Zaza Rate dependency of {beta}-adrenergic modulation of repolarizing currents in the guinea-pig ventricle J. Physiol., July 1, 2006; 574(1): 183 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Rampil, D. H. Moller, and A. H. Bell Isoflurane modulates genomic expression in rat amygdala. Anesth. Analg., May 1, 2006; 102(5): 1431 - 1438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Narayan T-Wave Alternans and the Susceptibility to Ventricular Arrhythmias J. Am. Coll. Cardiol., January 17, 2006; 47(2): 269 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Jespersen, M. Grunnet, and S.-P. Olesen The KCNQ1 Potassium Channel: From Gene to Physiological Function Physiology, December 1, 2005; 20(6): 408 - 416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guizy, C. Arias, M. David, T. Gonzalez, and C. Valenzuela {omega}-3 and {omega}-6 polyunsaturated fatty acids block HERG channels Am J Physiol Cell Physiol, November 1, 2005; 289(5): C1251 - C1260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Jost, L. Virag, M. Bitay, J. Takacs, C. Lengyel, P. Biliczki, Z. Nagy, G. Bogats, D. A. Lathrop, J. G. Papp, et al. Restricting Excessive Cardiac Action Potential and QT Prolongation: A Vital Role for IKs in Human Ventricular Muscle Circulation, September 6, 2005; 112(10): 1392 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lin, J. Guo, H. Gang, P. Wojciechowski, J. T. Wigle, and S. Zhang Intracellular K+ Is Required for the Inactivation-Induced High-Affinity Binding of Cisapride to HERG Channels Mol. Pharmacol., September 1, 2005; 68(3): 855 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dorn, F. Hermann, A. Ebneth, H. Bothmann, G. Trube, K. Christensen, and C. Apfel Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition J Biomol Screen, June 1, 2005; 10(4): 339 - 347. [Abstract] [PDF]
|
|
|
|
 |
|
 K.-H. Park, J. Piron, S. Dahimene, J. Merot, I. Baro, D. Escande, and G. Loussouarn Impaired KCNQ1-KCNE1 and Phosphatidylinositol-4,5-Bisphosphate Interaction Underlies the Long QT Syndrome Circ. Res., April 15, 2005; 96(7): 730 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aiba, W. Shimizu, M. Inagaki, T. Noda, S. Miyoshi, W.-G. Ding, D. P. Zankov, F. Toyoda, H. Matsuura, M. Horie, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil J. Am. Coll. Cardiol., January 18, 2005; 45(2): 300 - 307. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Clancy and R. S. Kass Inherited and Acquired Vulnerability to Ventricular Arrhythmias: Cardiac Na+ and K+ Channels Physiol Rev, January 1, 2005; 85(1): 33 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Noda, W. Shimizu, K. Satomi, K. Suyama, T. Kurita, N. Aihara, and S. Kamakura Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome Eur. Heart J., December 1, 2004; 25(23): 2149 - 2154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Bellocq, R. Wilders, J.-J. Schott, B. Louerat-Oriou, P. Boisseau, H. Le Marec, D. Escande, and I. Baro A Common Antitussive Drug, Clobutinol, Precipitates the Long QT Syndrome 2 Mol. Pharmacol., November 1, 2004; 66(5): 1093 - 1102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. Witchel, C. E. Dempsey, R. B. Sessions, M. Perry, J. T. Milnes, J. C. Hancox, and J. S. Mitcheson The Low-Potency, Voltage-Dependent HERG Blocker Propafenone--Molecular Determinants and Drug Trapping Mol. Pharmacol., November 1, 2004; 66(5): 1201 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Perry, M. J. de Groot, R. Helliwell, D. Leishman, M. Tristani-Firouzi, M. C. Sanguinetti, and J. Mitcheson Structural Determinants of HERG Channel Block by Clofilium and Ibutilide Mol. Pharmacol., August 1, 2004; 66(2): 240 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q Wang, S Chen, Q Chen, X Wan, J Shen, G A Hoeltge, A A Timur, M T Keating, and G E Kirsch The common SCN5A mutation R1193Q causes LQTS-type electrophysiological alterations of the cardiac sodium channel J. Med. Genet., May 1, 2004; 41(5): e66 - e66. [Full Text] [PDF]
|
|
|
|
|
|
R. Brugada, K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T. M. Menendez, J. Brugada, G. D. Pollevick, C. Wolpert, et al. Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG Circulation, January 6, 2004; 109(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Friederich, A. Solth, S. Schillemeit, and D. Isbrandt Local anaesthetic sensitivities of cloned HERG channels from human heart: comparison with HERG/MiRP1 and HERG/MiRP1T8A Br. J. Anaesth., January 1, 2004; 92(1): 93 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Kodirov, M. Brunner, J. M. Nerbonne, P. Buckett, G. F. Mitchell, and G. Koren Attenuation of IK,slow1 and IK,slow2 in Kv1/Kv2DN mice prolongs APD and QT intervals but does not suppress spontaneous or inducible arrhythmias Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H368 - H374. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Spencer and J. S. K. Sham Effects of Na+/Ca2+ exchange induced by SR Ca2+ release on action potentials and afterdepolarizations in guinea pig ventricular myocytes Am J Physiol Heart Circ Physiol, December 1, 2003; 285(6): H2552 - H2562. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Maguire, H. Wakimoto, V. V. Patel, P. E. Hammer, K. Gauvreau, and C. I. Berul Implications of ventricular arrhythmia vulnerability during murine electrophysiology studies Physiol Genomics, September 29, 2003; 15(1): 84 - 91. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Lange, F. Er, N. Gassanov, and U. C. Hoppe Andersen mutations of KCNJ2 suppress the native inward rectifier current IK1 in a dominant-negative fashion Cardiovasc Res, August 1, 2003; 59(2): 321 - 327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, S. Kodirov, M. Murata, P. D. Buckett, J. M. Nerbonne, and G. Koren Regional upregulation of Kv2.1-encoded current, IK,slow2, in Kv1DN mice is abolished by crossbreeding with Kv2DN mice Am J Physiol Heart Circ Physiol, February 1, 2003; 284(2): H491 - H500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wang, K. Della Penna, H. Wang, J. Karczewski, T. M. Connolly, K. S. Koblan, P. B. Bennett, and J. J. Salata Functional and pharmacological properties of canine ERG potassium channels Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H256 - H267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. H.T. Wehrens, M. A. Vos, P. A. Doevendans, and H. J.J. Wellens Novel Insights in the Congenital Long QT Syndrome Ann Intern Med, December 17, 2002; 137(12): 981 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, G. Seebohm, and M. C. Sanguinetti Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels PNAS, September 17, 2002; 99(19): 12461 - 12466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Makita, M. Horie, T. Nakamura, T. Ai, K. Sasaki, H. Yokoi, M. Sakurai, I. Sakuma, H. Otani, H. Sawa, et al. Drug-Induced Long-QT Syndrome Associated With a Subclinical SCN5A Mutation Circulation, September 3, 2002; 106(10): 1269 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Danik, C. Cabo, C. Chiello, S. Kang, A. L. Wit, and J. Coromilas Correlation of repolarization of ventricular monophasic action potential with ECG in the murine heart Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H372 - H381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shimizu, Y. Tanabe, T. Aiba, M. Inagaki, T. Kurita, K. Suyama, N. Nagaya, A. Taguchi, N. Aihara, K. Sunagawa, et al. Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the lqt1 and lqt2 forms of congenital long qt syndrome J. Am. Coll. Cardiol., June 19, 2002; 39(12): 1984 - 1991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Noda, H. Takaki, T. Kurita, K. Suyama, N. Nagaya, A. Taguchi, N. Aihara, S. Kamakura, K. Sunagawa, K. Nakamura, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome Eur. Heart J., June 2, 2002; 23(12): 975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Brugada and R. Roberts Brugada Syndrome: Why Are There Multiple Answers to a Simple Question? Circulation, December 18, 2001; 104(25): 3017 - 3019. [Full Text] [PDF]
|
|
|
|
|
|
H. Wedekind, J. P.P. Smits, E. Schulze-Bahr, R. Arnold, M. W. Veldkamp, T. Bajanowski, M. Borggrefe, B. Brinkmann, I. Warnecke, H. Funke, et al. De Novo Mutation in the SCN5A Gene Associated With Early Onset of Sudden Infant Death Circulation, September 4, 2001; 104(10): 1158 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Sosunov, E. P. Anyukhovsky, R. Z. Gainullin, A. Plotnikov, P. Danilo Jr., and M. R. Rosen Long-term electrophysiological effects of regional cardiac sympathetic denervation of the neonatal dog Cardiovasc Res, September 1, 2001; 51(4): 659 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Huang, M. Bitner-Glindzicz, L. Tranebjaerg, and A. Tinker A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome Cardiovasc Res, September 1, 2001; 51(4): 670 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-D. Huang, J. Chen, M. Lin, M. T. Keating, and M. C. Sanguinetti Long-QT Syndrome-Associated Missense Mutations in the Pore Helix of the HERG Potassium Channel Circulation, August 28, 2001; 104(9): 1071 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. COHEN, U. LOEWENTHAL, M. MATAR, and M. KOTLER Association of autonomic dysfunction and clozapine: Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication The British Journal of Psychiatry, August 1, 2001; 179(2): 167 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Abbott and S. A. N. Goldstein Potassium Channel Subunits: The MiRP Family Mol. Interv., June 1, 2001; 1(2): 95 - 107. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. C. Hoppe, E. Marban, and D. C. Johns Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1 PNAS, April 24, 2001; 98(9): 5335 - 5340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.L. Tan and K.I. Lie Treatment of tachyarrhythmias during pregnancy and lactation Eur. Heart J., March 2, 2001; 22(6): 458 - 464. [PDF]
|
|
|
|
|
|
G. Lande, F. Kyndt, I. Baro, D. Chabannes, P. Boisseau, J.-C. Pony, D. Escande, and H. Le Marec Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype Eur. Heart J., March 1, 2001; 22(5): 410 - 422. [Abstract] [PDF]
|
|
|
|
|
|
Y. Tanabe, M. Inagaki, T. Kurita, N. Nagaya, A. Taguchi, K. Suyama, N. Aihara, S. Kamakura, K. Sunagawa, K. Nakamura, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome J. Am. Coll. Cardiol., March 1, 2001; 37(3): 911 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Anderson, A. Mazur, T. Yang, and D. M. Roden Potassium Current Antagonist Properties and Proarrhythmic Consequences of Quinolone Antibiotics J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 806 - 810. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Unnikrishnan, J. P. Dutcher, N. Varshneya, R. Lucariello, M. Api, S. Garl, P. H. Wiernik, and S. Chiaramida Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide Blood, March 1, 2001; 97(5): 1514 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. O'Leary Inhibition of Human Ether-A-Go-Go Potassium Channels by Cocaine Mol. Pharmacol., February 1, 2001; 59(2): 269 - 277. [Abstract] [Full Text]
|
|
|
|
|
|
P. J. Schwartz, S. G. Priori, C. Spazzolini, A. J. Moss, G. M. Vincent, C. Napolitano, I. Denjoy, P. Guicheney, G. Breithardt, M. T. Keating, et al. Genotype-Phenotype Correlation in the Long-QT Syndrome : Gene-Specific Triggers for Life-Threatening Arrhythmias Circulation, January 2, 2001; 103(1): 89 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Chugh, S. B. Johnson, and D. L. Packer Altered response to ibutilide in a heart failure model Cardiovasc Res, January 1, 2001; 49(1): 94 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Pastore and D. S. Rosenbaum Role of Structural Barriers in the Mechanism of Alternans-Induced Reentry Circ. Res., December 8, 2000; 87(12): 1157 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. O'Brien, M. Apkon, C. I. Berul, H. T. Patel, K. Saupe, M. Spindler, J. S. Ingwall, and R. Zahler Phenotypical features of long Q-T syndrome in transgenic mice expressing human Na-K-ATPase alpha 3-isoform in hearts Am J Physiol Heart Circ Physiol, November 1, 2000; 279(5): H2133 - H2142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Merot, V. Probst, M. Debailleul, U. Gerlach, N. S. Moise, H. Le Marec, and F. Charpentier Electropharmacological characterization of cardiac repolarization in German shepherd dogs with an inherited syndrome of sudden death: abnormal response to potassium channel blockers J. Am. Coll. Cardiol., September 1, 2000; 36(3): 939 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M RODEN and M. E ANDERSON The pause that refreshes, or does it? Mechanisms in torsades de pointes Heart, September 1, 2000; 84(3): 235 - 237. [Full Text] [PDF]
|
|
|
|
|
|
D. M Roden ELECTROPHYSIOLOGY: Antiarrhythmic drugs: from mechanisms to clinical practice Heart, September 1, 2000; 84(3): 339 - 346. [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Schwartz, S. G. Priori, R. Dumaine, C. Napolitano, C. Antzelevitch, M. Stramba-Badiale, T. A. Richard, M. R. Berti, and R. Bloise A Molecular Link between the Sudden Infant Death Syndrome and the Long-QT Syndrome N. Engl. J. Med., July 27, 2000; 343(4): 262 - 267. [Full Text] [PDF]
|
|
|
|
|
|
J. Zhou, J. Yi, N. Hu, A. L. George Jr, and K. T. Murray Activation of Protein Kinase A Modulates Trafficking of the Human Cardiac Sodium Channel in Xenopus Oocytes Circ. Res., July 7, 2000; 87(1): 33 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-E. Chiang and D. M. Roden The long QT syndromes: genetic basis and clinical implications J. Am. Coll. Cardiol., July 1, 2000; 36(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J C Hancox, K C R Patel, and J V Jones Antiarrhythmics---from cell to clinic: past, present, and future Heart, July 1, 2000; 84(1): 14 - 24. [Full Text] [PDF]
|
|
|
|
|
|
J. F. Spear and E. N. Moore Modulation of arrhythmias by isoproterenol in a rabbit heart model of d-sotalol-induced long Q-T intervals Am J Physiol Heart Circ Physiol, July 1, 2000; 279(1): H15 - H25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S Viskin, R Fish, D Zeltser, B Belhassen, K Heller, D Brosh, S Laniado, and H V Barron Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent? Heart, June 1, 2000; 83(6): 661 - 666. [Abstract] [Full Text]
|
|
|
|
|
|
P. G.A. Volders, M. A. Vos, B. Szabo, K. R. Sipido, S.H.M. de Groot, A. P.M. Gorgels, H. J.J. Wellens, and R. Lazzara Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts Cardiovasc Res, June 1, 2000; 46(3): 376 - 392. [Full Text] [PDF]
|
|
|
|
|
|
J. Benhorin, R. Taub, M. Goldmit, B. Kerem, R. S. Kass, I. Windman, and A. Medina Effects of Flecainide in Patients With New SCN5A Mutation : Mutation-Specific Therapy for Long-QT Syndrome? Circulation, April 11, 2000; 101(14): 1698 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shimizu and C. Antzelevitch Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome J. Am. Coll. Cardiol., March 1, 2000; 35(3): 778 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Brugada, R Brugada, and J Brugada Sudden death in patients and relatives with the syndrome of right bundle branch block, ST segment elevation in the precordial leads V1to V3and sudden death Eur. Heart J., February 2, 2000; 21(4): 321 - 326. [Abstract] [PDF]
|
|
|
|
|
|
A. Mazur, D. M. Roden, and M. E. Anderson Systemic Administration of Calmodulin Antagonist W-7 or Protein Kinase A Inhibitor H-8 Prevents Torsade de Pointes in Rabbits Circulation, December 14, 1999; 100(24): 2437 - 2442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. A. Volders, K. R. Sipido, M. A. Vos, R. L. H. M. G. Spatjens, J. D. M. Leunissen, E. Carmeliet, and H. J. J. Wellens Downregulation of Delayed Rectifier K+ Currents in Dogs With Chronic Complete Atrioventricular Block and Acquired Torsades de Pointes Circulation, December 14, 1999; 100(24): 2455 - 2461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Fisher, D. Krikler, and K. A. Hallidie-Smith Familial polymorphic ventricular arrhythmias: A quarter century of successful medical treatment based on serial exercise-pharmacologic testing J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2015 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Rook, C. Bezzina Alshinawi, W.A. Groenewegen, I. C. van Gelder, A. C.G. van Ginneken, H. J. Jongsma, M. M.A.M. Mannens, and A. A.M. Wilde Human SCN5A gene mutations alter cardiac sodium channel kinetics and are associated with the Brugada syndrome Cardiovasc Res, December 1, 1999; 44(3): 507 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Rosen Leaky Dikes and Fibrillating Swine Circulation, November 9, 1999; 100(19): 1942 - 1944. [Full Text] [PDF]
|
|
|
|
|
|
D. Thomas, W. Zhang, C. A. Karle, S. Kathofer, W. Schols, W. Kubler, and J. Kiehn Deletion of Protein Kinase A Phosphorylation Sites in the HERG Potassium Channel Inhibits Activation Shift by Protein Kinase A J. Biol. Chem., September 24, 1999; 274(39): 27457 - 27462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Shuba, Y. Kasamaki, S. E. Jones, T. Ogura, J. R. McCullough, and T. F. McDonald Action Potentials, Contraction, and Membrane Currents in Guinea Pig Ventricular Preparations Treated with the Antispasmodic Agent Terodiline J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1417 - 1426. [Abstract] [Full Text]
|
|
|
|
|
|
A. Busjahn, H. Knoblauch, H.-D. Faulhaber, T. Boeckel, M. Rosenthal, R. Uhlmann, M. Hoehe, H. Schuster, and F. C. Luft QT Interval Is Linked to 2 Long-QT Syndrome Loci in Normal Subjects Circulation, June 22, 1999; 99(24): 3161 - 3164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wei, D. W. Wang, M. Alings, F. Fish, M. Wathen, D. M. Roden, and A. L. George Jr Congenital Long-QT Syndrome Caused by a Novel Mutation in a Conserved Acidic Domain of the Cardiac Na+ Channel Circulation, June 22, 1999; 99(24): 3165 - 3171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, L. B. MacMillan, R. B. McNeill, R. J. Colbran, and M. E. Anderson CaM kinase augments cardiac L-type Ca2+ current: a cellular mechanism for long Q-T arrhythmias Am J Physiol Heart Circ Physiol, June 1, 1999; 276(6): H2168 - H2178. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wu, D. M. Roden, and M. E. Anderson Calmodulin Kinase Inhibition Prevents Development of the Arrhythmogenic Transient Inward Current Circ. Res., April 30, 1999; 84(8): 906 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Mathur, J. Zhou, T. Babila, and G. Koren Ile-177 and Ser-180 in the S1 Segment Are Critically Important in Kv1.1 Channel Function J. Biol. Chem., April 23, 1999; 274(17): 11487 - 11493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chen, A. Zou, I. Splawski, M. T. Keating, and M. C. Sanguinetti Long QT Syndrome-associated Mutations in the Per-Arnt-Sim (PAS) Domain of HERG Potassium Channels Accelerate Channel Deactivation J. Biol. Chem., April 9, 1999; 274(15): 10113 - 10118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A Sosunov, E. P Anyukhovsky, A. Shvilkin, Motoki Hara, S. F Steinberg, P. Danilo Jr., M. R Rosen, N Sydney Moise, J. Merot, V. Probst, et al. Abnormal cardiac repolarization and impulse initiation in German shepherd dogs with inherited ventricular arrhythmias and sudden death Cardiovasc Res, April 1, 1999; 42(1): 65 - 79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Petrecca, R. Atanasiu, A. Akhavan, and A. Shrier N-linked glycosylation sites determine HERG channel surface membrane expression J. Physiol., February 15, 1999; 515(1): 41 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Alings and A. Wilde "Brugada" Syndrome : Clinical Data and Suggested Pathophysiological Mechanism Circulation, February 9, 1999; 99(5): 666 - 673. [Full Text] [PDF]
|
|
|
|
|
|
S. Kupershmidt, T. Yang, M. E. Anderson, A. Wessels, K. D. Niswender, M. A. Magnuson, and D. M. Roden Replacement by Homologous Recombination of the minK Gene With lacZ Reveals Restriction of minK Expression to the Mouse Cardiac Conduction System Circ. Res., February 5, 1999; 84(2): 146 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. M. Wilde, R. J. E. Jongbloed, P. A. Doevendans, D. R. Duren, R. N. W. Hauer, I. M. van Langen, J. P. van Tintelen, H. J. M. Smeets, H. Meyer, and J. L. M. C. Geelen Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1) J. Am. Coll. Cardiol., February 1, 1999; 33(2): 327 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Basilico Cardiovascular Disease in Athletes Am. J. Sports Med., January 1, 1999; 27(1): 108 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Anderson, A. P. Braun, Y. Wu, T. Lu, Y. Wu, H. Schulman, and R. J. Sung KN-93, an Inhibitor of Multifunctional Ca++/Calmodulin-Dependent Protein Kinase, Decreases Early Afterdepolarizations in Rabbit Heart J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 996 - 1006. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Sesti and S. A.N. Goldstein Single-Channel Characteristics of Wild-Type IKs Channels and Channels formed with Two MinK Mutants that Cause Long QT Syndrome J. Gen. Physiol., December 1, 1998; 112(6): 651 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Shimizu and C. Antzelevitch Cellular Basis for the ECG Features of the LQT1 Form of the Long-QT Syndrome : Effects of ß-Adrenergic Agonists and Antagonists and Sodium Channel Blockers on Transmural Dispersion of Repolarization and Torsade de Pointes Circulation, November 24, 1998; 98(21): 2314 - 2322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kupershmidt, D. J. Snyders, A. Raes, and D. M. Roden A K+ Channel Splice Variant Common in Human Heart Lacks a C-terminal Domain Required for Expression of Rapidly Activating Delayed Rectifier Current J. Biol. Chem., October 16, 1998; 273(42): 27231 - 27235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, J. H. Moller, C. E. Seidman, G. M. Vincent, H. C. Dietz, A. J. Moss, J. A. Towbin, H. M. Sondheimer, R. E. Pyeritz, G. McGee, et al. Impact of Laboratory Molecular Diagnosis on Contemporary Diagnostic Criteria for Genetically Transmitted Cardiovascular Diseases: Hypertrophic Cardiomyopathy, Long-QT Syndrome, and Marfan Syndrome : A Statement for Healthcare Professionals From the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association Circulation, October 6, 1998; 98(14): 1460 - 1471. [Full Text] [PDF]
|
|
|
|
|
|
C. Chouabe, M.-D. Drici, G. Romey, J. Barhanin, and M. Lazdunski HERG and KvLQT1/IsK, the Cardiac K+ Channels Involved in Long QT Syndromes, Are Targets for Calcium Channel Blockers Mol. Pharmacol., October 1, 1998; 54(4): 695 - 703. [Abstract] [Full Text]
|
|
|
|
|
|
J. Kiehn, C. Karle, D. Thomas, X. Yao, J. Brachmann, and W. Kubler HERG Potassium Channel Activation Is Shifted by Phorbol Esters via Protein Kinase A-dependent Pathways J. Biol. Chem., September 25, 1998; 273(39): 25285 - 25291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Babij, G. R. Askew, B. Nieuwenhuijsen, C.-M. Su, T. R. Bridal, B. Jow, T. M. Argentieri, J. Kulik, L. J. DeGennaro, W. Spinelli, et al. Inhibition of Cardiac Delayed Rectifier K+ Current by Overexpression of the Long-QT Syndrome HERG G628S Mutation in Transgenic Mice Circ. Res., September 21, 1998; 83(6): 668 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H L Tan and A A M Wilde T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm Heart, September 1, 1998; 80(3): 303 - 306. [Abstract] [Full Text]
|
|
|
|
|
|
M.-D. Drici, I. Arrighi, C. Chouabe, J. R. Mann, M. Lazdunski, G. Romey, and J. Barhanin Involvement of IsK-Associated K+ Channel in Heart Rate Control of Repolarization in a Murine Engineered Model of Jervell and Lange-Nielsen Syndrome Circ. Res., July 13, 1998; 83(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. G. Priori, P. J. Schwartz, C. Napolitano, L. Bianchi, A. Dennis, M. D. Fusco, A. M. Brown, and G. Casari A Recessive Variant of the Romano-Ward Long-QT Syndrome? Circulation, June 23, 1998; 97(24): 2420 - 2425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Locati, W. Zareba, A. J. Moss, P. J. Schwartz, G. M. Vincent, M. H. Lehmann, J. A. Towbin, S. G. Priori, C. Napolitano, J. L. Robinson, et al. Age- and Sex-Related Differences in Clinical Manifestations in Patients With Congenital Long-QT Syndrome : Findings From the International LQTS Registry Circulation, June 9, 1998; 97(22): 2237 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zou, Q. P Xu, and M. C Sanguinetti A mutation in the pore region of HERG K+ channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation J. Physiol., May 15, 1998; 509(1): 129 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Marban, T. Yamagishi, and G. F Tomaselli Structure and function of voltage-gated sodium channels J. Physiol., May 1, 1998; 508(3): 647 - 657. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||